{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:19:57Z","timestamp":1794604797763,"version":"4.9.1"},"reference-count":415,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261201500003I"],"award-info":[{"award-number":["HHSN261201500003I"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aggressive tumors pose ultra-challenges to drug resistance. Anti-cancer treatments are often unsuccessful, and single-cell technologies to rein drug resistance mechanisms are still fruitless. The National Cancer Institute defines aggressive cancers at the tissue level, describing them as those that spread rapidly, despite severe treatment. At the molecular, foundational level, the quantitative biophysics discipline defines aggressive cancers as harboring a large number of (overexpressed, or mutated) crucial signaling proteins in major proliferation pathways populating their active conformations, primed for their signal transduction roles. This comprehensive review explores highly aggressive cancers on the foundational and cell signaling levels, focusing on the differences between highly aggressive cancers and the more treatable ones. It showcases aggressive tumors as harboring massive, cancer-promoting, catalysis-primed oncogenic proteins, especially through certain overexpression scenarios, as predisposed aggressive tumor candidates. Our examples narrate strong activation of ERK1\/2, and other oncogenic proteins, through malfunctioning chromatin and crosslinked signaling, and how they activate multiple proliferation pathways. They show the increased cancer heterogeneity, plasticity, and drug resistance. Our review formulates the principles underlying cancer aggressiveness on the molecular level, discusses scenarios, and describes drug regimen (single drugs and drug combinations) for PDAC, NSCLC, CRC, HCC, breast and prostate cancers, glioblastoma, neuroblastoma, and leukemia as examples. All show overexpression scenarios of master transcription factors, transcription factors with gene fusions, copy number alterations, dysregulation of the epigenetic codes and epithelial-to-mesenchymal transitions in aggressive tumors, as well as high mutation loads of vital upstream signaling regulators, such as EGFR, c-MET, and K-Ras, befitting these principles.<\/jats:p>","DOI":"10.1038\/s41392-025-02129-7","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T18:02:56Z","timestamp":1739728976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Molecular principles underlying aggressive cancers"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-6415","authenticated-orcid":false,"given":"Ruth","family":"Nussinov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengi Ruken","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9402-4051","authenticated-orcid":false,"given":"Hyunbum","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2129_CR1","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.3390\/cancers13133209","volume":"13","author":"J Martinez-Useros","year":"2021","unstructured":"Martinez-Useros, J., Martin-Galan, M., Florez-Cespedes, M. & Garcia-Foncillas, J. Epigenetics of most aggressive solid tumors: pathways, targets and treatments. Cancers 13, 3209 (2021).","journal-title":"Cancers"},{"key":"2129_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/0008-5472.CAN-23-1148","volume":"84","author":"P Saggese","year":"2024","unstructured":"Saggese, P. et al. Glucose deprivation promotes pseudohypoxia and dedifferentiation in lung adenocarcinoma. Cancer Res. 84, 305\u2013327 (2024).","journal-title":"Cancer Res."},{"key":"2129_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109293","volume":"35","author":"AW Watson","year":"2021","unstructured":"Watson, A. W. et al. Breast tumor stiffness instructs bone metastasis via maintenance of mechanical conditioning. Cell Rep. 35, 109293 (2021).","journal-title":"Cell Rep."},{"key":"2129_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58995-4","volume":"10","author":"H Takahashi","year":"2020","unstructured":"Takahashi, H. et al. Biologically aggressive phenotype and anti-cancer immunity counterbalance in breast cancer with high mutation rate. Sci. Rep. 10, 1852 (2020).","journal-title":"Sci. Rep."},{"key":"2129_CR5","unstructured":"Docrates Cancer Center. The most aggressive cancers: pancreatic, lung and liver cancer show the fastest progression. https:\/\/www.docrates.com\/en\/the-most-aggressive-cancers\/ (2023)."},{"key":"2129_CR6","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1158\/1078-0432.CCR-18-1446","volume":"24","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition. Clin. Cancer Res. 24, 6594\u20136610 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2129_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01618-9","volume":"20","author":"T Xu","year":"2020","unstructured":"Xu, T. et al. Overexpression of protein regulator of cytokinesis 1 facilitates tumor growth and indicates unfavorable prognosis of patients with colon cancer. Cancer Cell Int. 20, 528 (2020).","journal-title":"Cancer Cell Int."},{"key":"2129_CR8","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.7150\/jca.40517","volume":"11","author":"R Zhang","year":"2020","unstructured":"Zhang, R. et al. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. J. Cancer 11, 2371\u20132381 (2020).","journal-title":"J. Cancer"},{"key":"2129_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147025","volume":"131","author":"Y He","year":"2021","unstructured":"He, Y. et al. FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J. Clin. Invest. 131, e147025 (2021).","journal-title":"J. Clin. Invest."},{"key":"2129_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10549-021-06142-6","volume":"187","author":"YF Wang","year":"2021","unstructured":"Wang, Y. F. et al. Overexpression of Stat3 increases circulating cfDNA in breast cancer. Breast Cancer Res. Treat. 187, 69\u201380 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"2129_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm14050463","volume":"14","author":"IC Bodea","year":"2024","unstructured":"Bodea, I. C. et al. HER2 overexpression in periampullary tumors according to anatomical and histological classification\u2014a systematic review. J. Pers. Med. 14, 463 (2024).","journal-title":"J. Pers. Med."},{"key":"2129_CR12","doi-asserted-by":"publisher","first-page":"eadm9211","DOI":"10.1126\/sciadv.adm9211","volume":"10","author":"R Nussinov","year":"2024","unstructured":"Nussinov, R., Zhang, W., Liu, Y. & Jang, H. Mitogen signaling strength and duration can control cell cycle decisions. Sci. Adv. 10, eadm9211 (2024).","journal-title":"Sci. Adv."},{"key":"2129_CR13","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1158\/0008-5472.CAN-22-2125","volume":"82","author":"R Nussinov","year":"2022","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. A new view of activating mutations in cancer. Cancer Res. 82, 4114\u20134123 (2022).","journal-title":"Cancer Res."},{"key":"2129_CR14","doi-asserted-by":"publisher","first-page":"106766","DOI":"10.1016\/j.bpc.2022.106766","volume":"283","author":"R Nussinov","year":"2022","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. Allostery, and how to define and measure signal transduction. Biophys. Chem. 283, 106766 (2022).","journal-title":"Biophys. Chem."},{"key":"2129_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41392-023-01329-3","volume":"8","author":"P Wang","year":"2023","unstructured":"Wang, P. et al. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1\/2. Signal Transduct. Target Ther. 8, 96 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06598-6","volume":"15","author":"J Xiao","year":"2024","unstructured":"Xiao, J. et al. Integrating spatial and single-cell transcriptomics reveals tumor heterogeneity and intercellular networks in colorectal cancer. Cell Death Dis. 15, 326 (2024).","journal-title":"Cell Death Dis."},{"key":"2129_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33619-9","volume":"13","author":"C Zuo","year":"2022","unstructured":"Zuo, C. et al. Elucidating tumor heterogeneity from spatially resolved transcriptomics data by multi-view graph collaborative learning. Nat. Commun. 13, 5962 (2022).","journal-title":"Nat. Commun."},{"key":"2129_CR18","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1073\/pnas.0813351106","volume":"106","author":"JP Gustin","year":"2009","unstructured":"Gustin, J. P. et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc. Natl Acad. Sci. USA 106, 2835\u20132840 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2129_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627\u2013644 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2129_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/onc.2012.53","volume":"32","author":"W Yuan","year":"2013","unstructured":"Yuan, W. et al. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 32, 318\u2013326 (2013).","journal-title":"Oncogene"},{"key":"2129_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5961","volume":"5","author":"X Wu","year":"2014","unstructured":"Wu, X. et al. Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat. Commun. 5, 4961 (2014).","journal-title":"Nat. Commun."},{"key":"2129_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0168-9525(00)02021-7","volume":"16","author":"SC Robertson","year":"2000","unstructured":"Robertson, S. C., Tynan, J. A. & Donoghue, D. J. RTK mutations and human syndromeswhen good receptors turn bad. Trends Genet. 16, 265\u2013271 (2000).","journal-title":"Trends Genet."},{"key":"2129_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du, Z. & Lovly, C. M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer 17, 58 (2018).","journal-title":"Mol. Cancer"},{"key":"2129_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-020-00420-3","volume":"6","author":"R Nussinov","year":"2021","unstructured":"Nussinov, R., Jang, H., Nir, G., Tsai, C. J. & Cheng, F. A new precision medicine initiative at the dawn of exascale computing. Signal Transduct. Target Ther. 6, 3 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR25","doi-asserted-by":"publisher","first-page":"eabm2059","DOI":"10.1126\/sciadv.abm2059","volume":"8","author":"R Nussinov","year":"2022","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. How can same-gene mutations promote both cancer and developmental disorders? Sci. Adv. 8, eabm2059 (2022).","journal-title":"Sci. Adv."},{"key":"2129_CR26","doi-asserted-by":"publisher","first-page":"106597","DOI":"10.1016\/j.nbd.2024.106597","volume":"199","author":"R Nussinov","year":"2024","unstructured":"Nussinov, R., Yavuz, B. R. & Jang, H. Single cell spatial biology over developmental time can decipher pediatric brain pathologies. Neurobiol. Dis. 199, 106597 (2024).","journal-title":"Neurobiol. Dis."},{"key":"2129_CR27","doi-asserted-by":"publisher","first-page":"167695","DOI":"10.1016\/j.jmb.2022.167695","volume":"434","author":"P Grudzien","year":"2022","unstructured":"Grudzien, P., Jang, H., Leschinsky, N., Nussinov, R. & Gaponenko, V. Conformational dynamics allows sampling of an \u201cActive-like\u201d state by oncogenic K-Ras-GDP. J. Mol. Biol. 434, 167695 (2022).","journal-title":"J. Mol. Biol."},{"key":"2129_CR28","doi-asserted-by":"publisher","first-page":"eabc2754","DOI":"10.1126\/science.abc2754","volume":"370","author":"T Xie","year":"2020","unstructured":"Xie, T., Saleh, T., Rossi, P. & Kalodimos, C. G. Conformational states dynamically populated by a kinase determine its function. Science 370, eabc2754 (2020).","journal-title":"Science"},{"key":"2129_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1021\/cb500870a","volume":"10","author":"M Tong","year":"2015","unstructured":"Tong, M. & Seeliger, M. A. Targeting conformational plasticity of protein kinases. ACS Chem. Biol. 10, 190\u2013200 (2015).","journal-title":"ACS Chem. Biol."},{"key":"2129_CR30","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1158\/0008-5472.CAN-22-0804","volume":"82","author":"MI Parker","year":"2022","unstructured":"Parker, M. I., Meyer, J. E., Golemis, E. A. & Dunbrack, R. L. Delineating the RAS conformational landscape. Cancer Res. 82, 2485\u20132498 (2022).","journal-title":"Cancer Res."},{"key":"2129_CR31","unstructured":"M\u00f6bitz, H. Conformational bias: a key concept for protein kinase inhibition. https:\/\/www.europeanpharmaceuticalreview.com\/article\/11289\/conformational-bias-a-key-concept-for-protein-kinase-inhibition\/ (2012)."},{"key":"2129_CR32","doi-asserted-by":"publisher","first-page":"20180330","DOI":"10.1098\/rsif.2018.0330","volume":"15","author":"D Petrovic","year":"2018","unstructured":"Petrovic, D., Risso, V. A., Kamerlin, S. C. L. & Sanchez-Ruiz, J. M. Conformational dynamics and enzyme evolution. J. R. Soc. Interface 15, 20180330 (2018).","journal-title":"J. R. Soc. Interface"},{"key":"2129_CR33","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/pro.3829","volume":"29","author":"CH Lo","year":"2020","unstructured":"Lo, C. H., Huber, E. C. & Sachs, J. N. Conformational states of TNFR1 as a molecular switch for receptor function. Protein Sci. 29, 1401\u20131415 (2020).","journal-title":"Protein Sci."},{"key":"2129_CR34","doi-asserted-by":"publisher","first-page":"102626","DOI":"10.1016\/j.sbi.2023.102626","volume":"81","author":"WS Tang","year":"2023","unstructured":"Tang, W. S., Zhong, E. D., Hanson, S. M., Thiede, E. H. & Cossio, P. Conformational heterogeneity and probability distributions from single-particle cryo-electron microscopy. Curr. Opin. Struct. Biol. 81, 102626 (2023).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"2129_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46715-9","volume":"15","author":"G Monteiro da Silva","year":"2024","unstructured":"Monteiro da Silva, G., Cui, J. Y., Dalgarno, D. C., Lisi, G. P. & Rubenstein, B. M. High-throughput prediction of protein conformational distributions with subsampled AlphaFold2. Nat. Commun. 15, 2464 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR36","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1021\/acs.jpclett.3c02600","volume":"15","author":"H Kawamukai","year":"2024","unstructured":"Kawamukai, H. et al. Conformational distribution of a multidomain protein measured by single-pair small-angle X-ray scattering. J. Phys. Chem. Lett. 15, 744\u2013750 (2024).","journal-title":"J. Phys. Chem. Lett."},{"key":"2129_CR37","doi-asserted-by":"publisher","first-page":"102722","DOI":"10.1016\/j.sbi.2023.102722","volume":"83","author":"R Nussinov","year":"2023","unstructured":"Nussinov, R., Liu, Y., Zhang, W. & Jang, H. Cell phenotypes can be predicted from propensities of protein conformations. Curr. Opin. Struct. Biol. 83, 102722 (2023).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"2129_CR38","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1039\/D3CB00114H","volume":"4","author":"R Nussinov","year":"2023","unstructured":"Nussinov, R., Liu, Y., Zhang, W. & Jang, H. Protein conformational ensembles in function: roles and mechanisms. RSC Chem. Biol. 4, 850\u2013864 (2023).","journal-title":"RSC Chem. Biol."},{"key":"2129_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2020.06.024","volume":"182","author":"J Vijg","year":"2020","unstructured":"Vijg, J. & Dong, X. Pathogenic mechanisms of somatic mutation and genome mosaicism in aging. Cell 182, 12\u201323 (2020).","journal-title":"Cell"},{"key":"2129_CR40","doi-asserted-by":"publisher","first-page":"e1007108","DOI":"10.1371\/journal.pgen.1007108","volume":"14","author":"RA Risques","year":"2018","unstructured":"Risques, R. A. & Kennedy, S. R. Aging and the rise of somatic cancer-associated mutations in normal tissues. PLoS Genet. 14, e1007108 (2018).","journal-title":"PLoS Genet."},{"key":"2129_CR41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/s41416-019-0721-1","volume":"122","author":"E Laconi","year":"2020","unstructured":"Laconi, E., Marongiu, F. & DeGregori, J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. Br. J. Cancer 122, 943\u2013952 (2020).","journal-title":"Br. J. Cancer"},{"key":"2129_CR42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.molmed.2023.04.002","volume":"29","author":"J Vijg","year":"2023","unstructured":"Vijg, J. et al. Mitigating age-related somatic mutation burden. Trends Mol. Med. 29, 530\u2013540 (2023).","journal-title":"Trends Mol. Med."},{"key":"2129_CR43","doi-asserted-by":"publisher","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. Anticancer drug resistance: an update and perspective. Drug Resist. Updat. 59, 100796 (2021).","journal-title":"Drug Resist. Updat."},{"key":"2129_CR44","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1182\/blood.2022019304","volume":"142","author":"E Molteni","year":"2023","unstructured":"Molteni, E. et al. Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity. Blood 142, 643\u2013657 (2023).","journal-title":"Blood"},{"key":"2129_CR45","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ajcp\/aqad075","volume":"160","author":"N Patel","year":"2023","unstructured":"Patel, N. & Calvo, K. R. How I diagnose myeloid neoplasms with germline predisposition. Am. J. Clin. Pathol. 160, 352\u2013364 (2023).","journal-title":"Am. J. Clin. Pathol."},{"key":"2129_CR46","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jtho.2023.05.028","volume":"18","author":"G Farinea","year":"2023","unstructured":"Farinea, G. et al. The role of germline mutations in thoracic malignancies: between myth and reality. J. Thorac. Oncol. 18, 1146\u20131164 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2129_CR47","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0057","volume":"30","author":"A Venizelos","year":"2023","unstructured":"Venizelos, A. et al. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr. Relat. Cancer 30, e230057 (2023).","journal-title":"Endocr. Relat. Cancer"},{"key":"2129_CR48","doi-asserted-by":"publisher","unstructured":"Demko, N. & Geyer, J. T. Updates on germline predisposition in pediatric hematologic malignancies: what is the role of flow cytometry? Cytometry B Clin. Cytom. https:\/\/doi.org\/10.1002\/cyto.b.22192 (2024).","DOI":"10.1002\/cyto.b.22192"},{"key":"2129_CR49","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/diagnostics13061046","volume":"13","author":"OA Orzan","year":"2023","unstructured":"Orzan, O. A. et al. Cutaneous melanoma and glioblastoma multiforme association-case presentation and literature review. Diagnostics 13, 1046 (2023).","journal-title":"Diagnostics"},{"key":"2129_CR50","doi-asserted-by":"publisher","first-page":"BSR20180511","DOI":"10.1042\/BSR20180511","volume":"38","author":"PM Dantonio","year":"2018","unstructured":"Dantonio, P. M. et al. Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy. Biosci. Rep. 38, BSR20180511 (2018).","journal-title":"Biosci. Rep."},{"key":"2129_CR51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.annepidem.2014.02.010","volume":"24","author":"PM Scarbrough","year":"2014","unstructured":"Scarbrough, P. M., Akushevich, I., Wrensch, M. & Il\u2019yasova, D. Exploring the association between melanoma and glioma risks. Ann. Epidemiol. 24, 469\u2013474 (2014).","journal-title":"Ann. Epidemiol."},{"key":"2129_CR52","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41568-022-00511-z","volume":"22","author":"C Barranco","year":"2022","unstructured":"Barranco, C. Strength lies in difference. Nat. Rev. Cancer 22, 547 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2129_CR53","unstructured":"Bigler, A. Study hints at why an aggressive form of brain cancer is hard to treat. https:\/\/www.broadinstitute.org\/news\/study-hints-why-aggressive-form-brain-cancer-hard-treat (2019)."},{"key":"2129_CR54","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849.e821 (2019).","journal-title":"Cell"},{"key":"2129_CR55","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.ccell.2021.05.005","volume":"39","author":"KP Simeonov","year":"2021","unstructured":"Simeonov, K. P. et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150\u20131162.e1159 (2021).","journal-title":"Cancer Cell"},{"key":"2129_CR56","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.1073\/pnas.1814279116","volume":"116","author":"V Modi","year":"2019","unstructured":"Modi, V. & Dunbrack, R. L. Jr. Defining a new nomenclature for the structures of active and inactive kinases. Proc. Natl Acad. Sci. USA 116, 6818\u20136827 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2129_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.tips.2024.04.012","volume":"45","author":"R Nussinov","year":"2024","unstructured":"Nussinov, R., Yavuz, B. R. & Jang, H. Anticancer drugs: how to select small molecule combinations? Trends Pharm. Sci. 45, 503\u2013519 (2024).","journal-title":"Trends Pharm. Sci."},{"key":"2129_CR58","doi-asserted-by":"publisher","unstructured":"Nussinov, R. & Jang, H. The value of protein allostery in rational anticancer drug design: an update. Expert Opin. Drug Deliv. https:\/\/doi.org\/10.1080\/17460441.17462024.12384467 (2024).","DOI":"10.1080\/17460441.17462024.12384467"},{"key":"2129_CR59","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.tips.2024.05.001","volume":"45","author":"R Nussinov","year":"2024","unstructured":"Nussinov, R. et al. Directions to overcome therapy resistance in cancer. Trends Pharm. Sci. 45, 467\u2013471 (2024).","journal-title":"Trends Pharm. Sci."},{"key":"2129_CR60","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks, P. et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 603, 166\u2013173 (2022).","journal-title":"Nature"},{"key":"2129_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-02915-y","volume":"11","author":"C Hu","year":"2024","unstructured":"Hu, C. et al. Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer. Sci. Data 11, 74 (2024).","journal-title":"Sci. Data"},{"key":"2129_CR62","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/cancers13040669","volume":"13","author":"Y Gilad","year":"2021","unstructured":"Gilad, Y., Gellerman, G., Lonard, D. M. & O\u2019Malley, B. W. Drug combination in cancer treatment\u2014from cocktails to conjugated combinations. Cancers 13, 669 (2021).","journal-title":"Cancers"},{"key":"2129_CR63","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/1878-0261.13377","volume":"17","author":"A Mulero-Sanchez","year":"2023","unstructured":"Mulero-Sanchez, A. et al. Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Mol. Oncol. 17, 964\u2013980 (2023).","journal-title":"Mol. Oncol."},{"key":"2129_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47166-y","volume":"15","author":"D Banerjee","year":"2024","unstructured":"Banerjee, D. et al. Lineage specific transcription factor waves reprogram neuroblastoma from self-renewal to differentiation. Nat. Commun. 15, 3432 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00272-w","volume":"6","author":"R Ge","year":"2022","unstructured":"Ge, R., Wang, Z. & Cheng, L. Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. NPJ Precis. Oncol. 6, 31 (2022).","journal-title":"NPJ Precis. Oncol."},{"key":"2129_CR66","unstructured":"Halliday, A. Tumor heterogeneity: navigating the next frontier in cancer research. https:\/\/www.technologynetworks.com\/cancer-research\/articles\/tumor-heterogeneity-navigating-the-next-frontier-in-cancer-research-383052 (2024)."},{"key":"2129_CR67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","volume":"43","author":"GR Bhat","year":"2024","unstructured":"Bhat, G. R. et al. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev. 43, 197\u2013228 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"2129_CR68","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang, A., Miao, K., Sun, H. & Deng, C. X. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int. J. Biol. Sci. 18, 3019\u20133033 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"2129_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0900-y","volume":"15","author":"DR Caswell","year":"2017","unstructured":"Caswell, D. R. & Swanton, C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 15, 133 (2017).","journal-title":"BMC Med."},{"key":"2129_CR70","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1200\/EDBK_175524","volume":"37","author":"WS El-Deiry","year":"2017","unstructured":"El-Deiry, W. S., Taylor, B. & Neal, J. W. Tumor evolution, heterogeneity, and therapy for our patients with advanced cancer: how far have we come? Am. Soc. Clin. Oncol. Educ. Book 37, e8\u2013e15 (2017).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"2129_CR71","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ccell.2022.08.021","volume":"40","author":"AC Anderson","year":"2022","unstructured":"Anderson, A. C. et al. Spatial transcriptomics. Cancer Cell 40, 895\u2013900 (2022).","journal-title":"Cancer Cell"},{"key":"2129_CR72","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.5966\/sctm.2014-0090","volume":"3","author":"Y Yamada","year":"2014","unstructured":"Yamada, Y., Haga, H. & Yamada, Y. Concise review: dedifferentiation meets cancer development: proof of concept for epigenetic cancer. Stem Cells Transl. Med. 3, 1182\u20131187 (2014).","journal-title":"Stem Cells Transl. Med."},{"key":"2129_CR73","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.semdp.2020.09.002","volume":"38","author":"E Baraban","year":"2021","unstructured":"Baraban, E. & Cooper, K. Dedifferentiated and undifferentiated neoplasms: a conceptual approach. Semin. Diagn. Pathol. 38, 119\u2013126 (2021).","journal-title":"Semin. Diagn. Pathol."},{"key":"2129_CR74","unstructured":"National Cancer Institute. Tumor grade. https:\/\/www.cancer.gov\/about-cancer\/diagnosis-staging\/diagnosis\/tumor-grade (2022)."},{"key":"2129_CR75","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-023-05706-4","volume":"616","author":"C Martinez-Ruiz","year":"2023","unstructured":"Martinez-Ruiz, C. et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature 616, 543\u2013552 (2023).","journal-title":"Nature"},{"key":"2129_CR76","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41576-022-00553-x","volume":"24","author":"Z Seferbekova","year":"2023","unstructured":"Seferbekova, Z., Lomakin, A., Yates, L. R. & Gerstung, M. Spatial biology of cancer evolution. Nat. Rev. Genet. 24, 295\u2013313 (2023).","journal-title":"Nat. Rev. Genet."},{"key":"2129_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02003-0","volume":"23","author":"JK Park","year":"2024","unstructured":"Park, J. K. et al. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications. Mol. Cancer 23, 87 (2024).","journal-title":"Mol. Cancer"},{"key":"2129_CR78","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.molcel.2019.03.009","volume":"73","author":"R Chaligne","year":"2019","unstructured":"Chaligne, R., Nam, A. S. & Landau, D. A. TARGET-seq takes aim at cancer evolution through multi-omics single-cell genotyping and transcriptomics. Mol. Cell 73, 1092\u20131094 (2019).","journal-title":"Mol. Cell"},{"key":"2129_CR79","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ccell.2023.02.019","volume":"41","author":"Y Hoogstrate","year":"2023","unstructured":"Hoogstrate, Y. et al. Transcriptome analysis reveals tumor microenvironment changes in glioblastoma. Cancer Cell 41, 678\u2013692.e677 (2023).","journal-title":"Cancer Cell"},{"key":"2129_CR80","doi-asserted-by":"publisher","first-page":"20130787","DOI":"10.1098\/rsif.2013.0787","volume":"10","author":"C Li","year":"2013","unstructured":"Li, C. & Wang, J. Quantifying Waddington landscapes and paths of non-adiabatic cell fate decisions for differentiation, reprogramming and transdifferentiation. J. R. Soc. Interface 10, 20130787 (2013).","journal-title":"J. R. Soc. Interface"},{"key":"2129_CR81","doi-asserted-by":"publisher","first-page":"8257","DOI":"10.1073\/pnas.1017017108","volume":"108","author":"J Wang","year":"2011","unstructured":"Wang, J., Zhang, K., Xu, L. & Wang, E. Quantifying the Waddington landscape and biological paths for development and differentiation. Proc. Natl Acad. Sci. USA 108, 8257\u20138262 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2129_CR82","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.cell.2011.05.027","volume":"145","author":"N Iovino","year":"2011","unstructured":"Iovino, N. & Cavalli, G. Rolling ES cells down the Waddington landscape with Oct4 and Sox2. Cell 145, 815\u2013817 (2011).","journal-title":"Cell"},{"key":"2129_CR83","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1242\/jeb.120071","volume":"218","author":"D Noble","year":"2015","unstructured":"Noble, D. Conrad Waddington and the origin of epigenetics. J. Exp. Biol. 218, 816\u2013818 (2015).","journal-title":"J. Exp. Biol."},{"key":"2129_CR84","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s41563-022-01323-0","volume":"21","author":"CL Marchant","year":"2022","unstructured":"Marchant, C. L., Malmi-Kakkada, A. N., Espina, J. A. & Barriga, E. H. Cell clusters softening triggers collective cell migration in vivo. Nat. Mater. 21, 1314\u20131323 (2022).","journal-title":"Nat. Mater."},{"key":"2129_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abp8416","volume":"8","author":"DL Pages","year":"2022","unstructured":"Pages, D. L. et al. Cell clusters adopt a collective amoeboid mode of migration in confined nonadhesive environments. Sci. Adv. 8, eabp8416 (2022).","journal-title":"Sci. Adv."},{"key":"2129_CR86","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.cell.2020.08.045","volume":"183","author":"ED Wrenn","year":"2020","unstructured":"Wrenn, E. D. et al. Regulation of collective metastasis by nanolumenal signaling. Cell 183, 395\u2013410.e319 (2020).","journal-title":"Cell"},{"key":"2129_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45902-y","volume":"15","author":"YY Kim","year":"2024","unstructured":"Kim, Y. Y. et al. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma. Nat. Commun. 15, 1703 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2008.03.035","volume":"270","author":"CM Linardic","year":"2008","unstructured":"Linardic, C. M. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett. 270, 10\u201318 (2008).","journal-title":"Cancer Lett."},{"key":"2129_CR89","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s12276-023-00934-0","volume":"55","author":"HH Zhuang","year":"2023","unstructured":"Zhuang, H. H., Qu, Q., Teng, X. Q., Dai, Y. H. & Qu, J. Superenhancers as master gene regulators and novel therapeutic targets in brain tumors. Exp. Mol. Med. 55, 290\u2013303 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2129_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13046-022-02506-y","volume":"41","author":"M Li","year":"2022","unstructured":"Li, M. et al. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma. J. Exp. Clin. Cancer Res. 41, 311 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2129_CR91","doi-asserted-by":"publisher","first-page":"18556","DOI":"10.1073\/pnas.0509360102","volume":"102","author":"J Lotem","year":"2005","unstructured":"Lotem, J., Netanely, D., Domany, E. & Sachs, L. Human cancers overexpress genes that are specific to a variety of normal human tissues. Proc. Natl Acad. Sci. USA 102, 18556\u201318561 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2129_CR92","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish, A. et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618, 598\u2013606 (2023).","journal-title":"Nature"},{"key":"2129_CR93","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"2129_CR94","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564\u20131579 (2023).","journal-title":"Cell"},{"key":"2129_CR95","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s43018-021-00321-6","volume":"3","author":"I Khan","year":"2022","unstructured":"Khan, I. & Steeg, P. S. Keeping brain metastases dormant. Nat. Cancer 3, 3\u20135 (2022).","journal-title":"Nat. Cancer"},{"key":"2129_CR96","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s10555-023-10131-0","volume":"42","author":"I Khan","year":"2023","unstructured":"Khan, I. & Steeg, P. S. A perspective on the metastasis suppressor field. Cancer Metastasis Rev. 42, 1061\u20131063 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"2129_CR97","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/labinvest.2017.104","volume":"98","author":"I Khan","year":"2018","unstructured":"Khan, I. & Steeg, P. S. Metastasis suppressors: functional pathways. Lab. Invest. 98, 198\u2013210 (2018).","journal-title":"Lab. Invest."},{"key":"2129_CR98","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A. & Fares, Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct. Target Ther. 5, 28 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR99","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1158\/0008-5472.CAN-19-0458","volume":"79","author":"DR Welch","year":"2019","unstructured":"Welch, D. R. & Hurst, D. R. Defining the hallmarks of metastasis. Cancer Res 79, 3011\u20133027 (2019).","journal-title":"Cancer Res"},{"key":"2129_CR100","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s10555-023-10130-1","volume":"42","author":"DR Welch","year":"2023","unstructured":"Welch, D. R. Metastasis suppressors: a paradigm shift in cancer biology. Cancer Metastasis Rev. 42, 1057\u20131059 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"2129_CR101","doi-asserted-by":"publisher","first-page":"13130","DOI":"10.1523\/JNEUROSCI.3583-07.2007","volume":"27","author":"M Silies","year":"2007","unstructured":"Silies, M. et al. Glial cell migration in the eye disc. J. Neurosci. 27, 13130\u201313139 (2007).","journal-title":"J. Neurosci."},{"key":"2129_CR102","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1749-6632.1991.tb15602.x","volume":"633","author":"TN Stitt","year":"1991","unstructured":"Stitt, T. N., Gasser, U. E. & Hatten, M. E. Molecular mechanisms of glial-guided neuronal migration. Ann. N. Y. Acad. Sci. 633, 113\u2013121 (1991).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2129_CR103","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41586-023-06981-x","volume":"626","author":"MA Nascimento","year":"2024","unstructured":"Nascimento, M. A. et al. Protracted neuronal recruitment in the temporal lobes of young children. Nature 626, 1056\u20131065 (2024).","journal-title":"Nature"},{"key":"2129_CR104","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.84019","volume":"12","author":"A Francou","year":"2023","unstructured":"Francou, A., Anderson, K. V. & Hadjantonakis, A. K. A ratchet-like apical constriction drives cell ingression during the mouse gastrulation EMT. Elife 12, e84019 (2023).","journal-title":"Elife"},{"key":"2129_CR105","doi-asserted-by":"publisher","first-page":"100899","DOI":"10.1016\/j.tranon.2020.100899","volume":"14","author":"JS Wu","year":"2021","unstructured":"Wu, J. S. et al. Plasticity of cancer cell invasion: patterns and mechanisms. Transl. Oncol. 14, 100899 (2021).","journal-title":"Transl. Oncol."},{"key":"2129_CR106","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.trecan.2021.07.001","volume":"7","author":"E Schuster","year":"2021","unstructured":"Schuster, E. et al. Better together: circulating tumor cell clustering in metastatic cancer. Trends Cancer 7, 1020\u20131032 (2021).","journal-title":"Trends Cancer"},{"key":"2129_CR107","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.20170494","volume":"214","author":"D Fang","year":"2017","unstructured":"Fang, D. & Zhu, J. Dynamic balance between master transcription factors determines the fates and functions of CD4 T cell and innate lymphoid cell subsets. J. Exp. Med. 214, 1861\u20131876 (2017).","journal-title":"J. Exp. Med."},{"key":"2129_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03558-9","volume":"11","author":"J Li","year":"2024","unstructured":"Li, J. et al. A single-cell chromatin accessibility dataset of human primed and naive pluripotent stem cell-derived teratoma. Sci. Data 11, 725 (2024).","journal-title":"Sci. Data"},{"key":"2129_CR109","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2217\/epi-2023-0409","volume":"16","author":"M Lavaud","year":"2024","unstructured":"Lavaud, M. et al. Super-enhancers: drivers of cells\u2019 identities and cells\u2019 debacles. Epigenomics 16, 681\u2013700 (2024).","journal-title":"Epigenomics"},{"key":"2129_CR110","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm7020021","volume":"7","author":"AD Guarnaccia","year":"2018","unstructured":"Guarnaccia, A. D. & Tansey, W. P. Moonlighting with WDR5: a cellular multitasker. J. Clin. Med. 7, 21 (2018).","journal-title":"J. Clin. Med."},{"key":"2129_CR111","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/life11101082","volume":"11","author":"C Poulard","year":"2021","unstructured":"Poulard, C., Noureddine, L. M., Pruvost, L. & Le Romancer, M. Structure, activity, and function of the protein lysine methyltransferase G9a. Life 11, 1082 (2021).","journal-title":"Life"},{"key":"2129_CR112","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrm3949","volume":"16","author":"S Heinz","year":"2015","unstructured":"Heinz, S., Romanoski, C. E., Benner, C. & Glass, C. K. The selection and function of cell type-specific enhancers. Nat. Rev. Mol. Cell Biol. 16, 144\u2013154 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2129_CR113","first-page":"216","volume":"84","author":"S Yoshino","year":"2022","unstructured":"Yoshino, S. & Suzuki, H. I. The molecular understanding of super-enhancer dysregulation in cancer. Nagoya J. Med. Sci. 84, 216\u2013229 (2022).","journal-title":"Nagoya J. Med. Sci."},{"key":"2129_CR114","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.3390\/ijms25105475","volume":"25","author":"L Cappabianca","year":"2024","unstructured":"Cappabianca, L. et al. Molecular characterization and inhibition of a novel stress-induced mitochondrial protecting role for misfolded TrkAIII in human SH-SY5Y neuroblastoma cells. Int. J. Mol. Sci. 25, 5475 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2129_CR115","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.urology.2023.12.011","volume":"185","author":"L Peard","year":"2024","unstructured":"Peard, L., Ziada, A., James, A., Radulescu, V. & Saltzman, A. F. Neuroblastoma in a newborn female. Urology 185, 80\u201383 (2024).","journal-title":"Urology"},{"key":"2129_CR116","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/cancers15133279","volume":"15","author":"C Bottino","year":"2023","unstructured":"Bottino, C., Vitale, C., Dondero, A. & Castriconi, R. B7-H3 in pediatric tumors: far beyond neuroblastoma. Cancers 15, 3279 (2023).","journal-title":"Cancers"},{"key":"2129_CR117","doi-asserted-by":"publisher","first-page":"101771","DOI":"10.1016\/j.molmet.2023.101771","volume":"75","author":"WJ Smiles","year":"2023","unstructured":"Smiles, W. J., Catalano, L., Stefan, V. E., Weber, D. D. & Kofler, B. Metabolic protein kinase signalling in neuroblastoma. Mol. Metab. 75, 101771 (2023).","journal-title":"Mol. Metab."},{"key":"2129_CR118","doi-asserted-by":"publisher","first-page":"1022192","DOI":"10.3389\/fendo.2023.1022192","volume":"14","author":"N Bechmann","year":"2023","unstructured":"Bechmann, N., Westermann, F. & Eisenhofer, G. HIF and MYC signaling in adrenal neoplasms of the neural crest: implications for pediatrics. Front. Endocrinol. 14, 1022192 (2023).","journal-title":"Front. Endocrinol."},{"key":"2129_CR119","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/jcp-2022-208476","volume":"76","author":"N Bhardwaj","year":"2023","unstructured":"Bhardwaj, N., Das, G. & Srinivasan, R. Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene or MYCN gene. J. Clin. Pathol. 76, 518\u2013523 (2023).","journal-title":"J. Clin. Pathol."},{"key":"2129_CR120","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.3390\/cancers14246212","volume":"14","author":"J Almeida","year":"2022","unstructured":"Almeida, J. et al. Deciphering the role of p53 and TAp73 in neuroblastoma: from pathogenesis to treatment. Cancers 14, 6212 (2022).","journal-title":"Cancers"},{"key":"2129_CR121","doi-asserted-by":"publisher","unstructured":"Bobin, C. et al. Sequential analysis of cfDNA reveals clonal evolution in neuroblastoma patients receiving ALK targeted therapy. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-1124-0753 (2024).","DOI":"10.1158\/1078-0432.CCR-1124-0753"},{"key":"2129_CR122","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/cancers16071343","volume":"16","author":"E Secomandi","year":"2024","unstructured":"Secomandi, E. et al. Differential competitive growth of transgenic subclones of neuroblastoma cells expressing different levels of cathepsin D co-cultured in 2D and 3D in response to EGF: implications in tumor heterogeneity and metastasis. Cancers 16, 1343 (2024).","journal-title":"Cancers"},{"key":"2129_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43564-w","volume":"14","author":"M Schoof","year":"2023","unstructured":"Schoof, M. et al. Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures. Nat. Commun. 14, 7717 (2023).","journal-title":"Nat. Commun."},{"key":"2129_CR124","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/mc.23745","volume":"63","author":"J Hu","year":"2024","unstructured":"Hu, J. et al. Anlotinib induces neuronal-like differentiation of neuroblastoma by downregulating CRMP5. Mol. Carcinog. 63, 1559\u20131571 (2024).","journal-title":"Mol. Carcinog."},{"key":"2129_CR125","doi-asserted-by":"publisher","unstructured":"Ekstrom, T. L. et al. USP44 overexpression drives a MYC-like gene expression program in neuroblastoma through epigenetic reprogramming. Mol. Cancer Res. https:\/\/doi.org\/10.1158\/1541-7786.MCR-1123-0454 (2024).","DOI":"10.1158\/1541-7786.MCR-1123-0454"},{"key":"2129_CR126","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1111\/cas.15815","volume":"114","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. TAF1D promotes proliferation by transcriptionally activating G2\/M phase-related genes in MYCN-amplified neuroblastoma. Cancer Sci. 114, 2860\u20132870 (2023).","journal-title":"Cancer Sci."},{"key":"2129_CR127","first-page":"e173337","volume":"9","author":"S Mei","year":"2024","unstructured":"Mei, S. et al. Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature. JCI Insight 9, e173337 (2024).","journal-title":"JCI Insight"},{"key":"2129_CR128","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1158\/2767-9764.CRC-23-0154","volume":"3","author":"D Banerjee","year":"2023","unstructured":"Banerjee, D. et al. Activating transcription factor 5 promotes neuroblastoma metastasis by inducing anoikis resistance. Cancer Res. Commun. 3, 2518\u20132530 (2023).","journal-title":"Cancer Res. Commun."},{"key":"2129_CR129","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12957-023-03011-y","volume":"21","author":"S Liu","year":"2023","unstructured":"Liu, S. et al. Metastasis pattern and prognosis in children with neuroblastoma. World J. Surg. Oncol. 21, 130 (2023).","journal-title":"World J. Surg. Oncol."},{"key":"2129_CR130","doi-asserted-by":"publisher","first-page":"77","DOI":"10.25259\/SNI_1137_2022","volume":"14","author":"C Heskett","year":"2023","unstructured":"Heskett, C., Kabangu, J. L., Bhargav, A., Chamoun, R. & Ohiorhenuan, I. Metastatic esthesioneuroblastoma with widespread recurrence to the central nervous system. Surg. Neurol. Int 14, 77 (2023).","journal-title":"Surg. Neurol. Int"},{"key":"2129_CR131","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1158\/0008-5472.CAN-22-2042","volume":"83","author":"M Xu","year":"2023","unstructured":"Xu, M. et al. HAND2 assists MYCN enhancer invasion to regulate a noradrenergic neuroblastoma phenotype. Cancer Res. 83, 686\u2013699 (2023).","journal-title":"Cancer Res."},{"key":"2129_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-4-35","volume":"4","author":"X Guo","year":"2011","unstructured":"Guo, X., Chen, Q. R., Song, Y. K., Wei, J. S. & Khan, J. Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status. BMC Med. Genomics 4, 35 (2011).","journal-title":"BMC Med. Genomics"},{"key":"2129_CR133","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/01.mop.0000150631.60571.89","volume":"17","author":"JM Maris","year":"2005","unstructured":"Maris, J. M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatr. 17, 7\u201313 (2005).","journal-title":"Curr. Opin. Pediatr."},{"key":"2129_CR134","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","volume":"369","author":"JM Maris","year":"2007","unstructured":"Maris, J. M., Hogarty, M. D., Bagatell, R. & Cohn, S. L. Neuroblastoma. Lancet 369, 2106\u20132120 (2007).","journal-title":"Lancet"},{"key":"2129_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47945-7","volume":"15","author":"IM Saldana-Guerrero","year":"2024","unstructured":"Saldana-Guerrero, I. M. et al. A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations. Nat. Commun. 15, 3745 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR136","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13046-022-02281-w","volume":"41","author":"M Ponzoni","year":"2022","unstructured":"Ponzoni, M. et al. Recent advances in the developmental origin of neuroblastoma: an overview. J. Exp. Clin. Cancer Res. 41, 92 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2129_CR137","unstructured":"Tonini, G. P. in Neuroblastoma\u2014Current State and Recent Updates (ed. Gowda, C.) (IntechOpen Limited, 2017)."},{"key":"2129_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04635-w","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. PCLAF promotes neuroblastoma G1\/S cell cycle progression via the E2F1\/PTTG1 axis. Cell Death Dis. 13, 178 (2022).","journal-title":"Cell Death Dis."},{"key":"2129_CR139","doi-asserted-by":"publisher","first-page":"625332","DOI":"10.3389\/fonc.2020.625332","volume":"10","author":"R Liu","year":"2020","unstructured":"Liu, R., Shi, P., Wang, Z., Yuan, C. & Cui, H. Molecular mechanisms of MYCN dysregulation in cancers. Front. Oncol. 10, 625332 (2020).","journal-title":"Front. Oncol."},{"key":"2129_CR140","doi-asserted-by":"publisher","first-page":"a040956","DOI":"10.1101\/cshperspect.a040956","volume":"14","author":"B Gryder","year":"2022","unstructured":"Gryder, B., Scacheri, P. C., Ried, T. & Khan, J. Chromatin mechanisms driving cancer. Cold Spring Harb. Perspect. Biol. 14, a040956 (2022).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2129_CR141","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002240","volume":"22","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription. PLoS Biol. 22, e3002240 (2024).","journal-title":"PLoS Biol."},{"key":"2129_CR142","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1093\/nar\/gkaa051","volume":"48","author":"AF Bryan","year":"2020","unstructured":"Bryan, A. F. et al. WDR5 is a conserved regulator of protein synthesis gene expression. Nucleic Acids Res. 48, 2924\u20132941 (2020).","journal-title":"Nucleic Acids Res."},{"key":"2129_CR143","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41588-019-0547-z","volume":"52","author":"RP Koche","year":"2020","unstructured":"Koche, R. P. et al. Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. Nat. Genet. 52, 29\u201334 (2020).","journal-title":"Nat. Genet."},{"key":"2129_CR144","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/ng.3921","volume":"49","author":"V Boeva","year":"2017","unstructured":"Boeva, V. et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat. Genet. 49, 1408\u20131413 (2017).","journal-title":"Nat. Genet."},{"key":"2129_CR145","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/ng.3899","volume":"49","author":"T van Groningen","year":"2017","unstructured":"van Groningen, T. et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat. Genet. 49, 1261\u20131266 (2017).","journal-title":"Nat. Genet."},{"key":"2129_CR146","unstructured":"United States Environmental Protection Agency. Health\u2014neurodevelopmental disorders. https:\/\/www.epa.gov\/americaschildrenenvironment\/health-neurodevelopmental-disorders (2023)."},{"key":"2129_CR147","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1200\/JCO.2017.73.0242","volume":"35","author":"D Sturm","year":"2017","unstructured":"Sturm, D., Pfister, S. M. & Jones, D. T. W. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J. Clin. Oncol. 35, 2370\u20132377 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2129_CR148","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.tins.2020.05.004","volume":"43","author":"I Parenti","year":"2020","unstructured":"Parenti, I., Rabaneda, L. G., Schoen, H. & Novarino, G. Neurodevelopmental disorders: from genetics to functional pathways. Trends Neurosci. 43, 608\u2013621 (2020).","journal-title":"Trends Neurosci."},{"key":"2129_CR149","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1126\/science.aac8128","volume":"350","author":"L Kunz","year":"2015","unstructured":"Kunz, L. et al. Reduced grid-cell-like representations in adults at genetic risk for Alzheimer\u2019s disease. Science 350, 430\u2013433 (2015).","journal-title":"Science"},{"key":"2129_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-019-0507-7","volume":"12","author":"J Song","year":"2019","unstructured":"Song, J. et al. Dysregulation of neuron differentiation in an autistic savant with exceptional memory. Mol. Brain 12, 91 (2019).","journal-title":"Mol. Brain"},{"key":"2129_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.085","volume":"31","author":"K Zhang","year":"2020","unstructured":"Zhang, K. et al. Imbalance of excitatory\/inhibitory neuron differentiation in neurodevelopmental disorders with an NR2F1 point mutation. Cell Rep. 31, 107521 (2020).","journal-title":"Cell Rep."},{"key":"2129_CR152","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1440-1681.1999.02987.x","volume":"26","author":"NR Saunders","year":"1999","unstructured":"Saunders, N. R., Habgood, M. D. & Dziegielewska, K. M. Barrier mechanisms in the brain, II. Immature brain. Clin. Exp. Pharm. Physiol. 26, 85\u201391 (1999).","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"2129_CR153","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrc3655","volume":"14","author":"D Sturm","year":"2014","unstructured":"Sturm, D. et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat. Rev. Cancer 14, 92\u2013107 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"2129_CR154","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-024-00503-9","volume":"13","author":"G Gallo-Oller","year":"2024","unstructured":"Gallo-Oller, G. et al. TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma. Exp. Hematol. Oncol. 13, 38 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"2129_CR155","unstructured":"National Cancer Institute. Master regulators flip the switch on neuroblastoma\u2019s developmental state. https:\/\/ccr.cancer.gov\/news\/article\/master-regulators-flip-the-switch-on-neuroblastomas-developmental-state (2024)."},{"key":"2129_CR156","unstructured":"American Cancer Society. Chemotherapy and related drugs for neuroblastoma. https:\/\/www.cancer.org\/cancer\/types\/neuroblastoma\/treating\/chemotherapy.html (2023)."},{"key":"2129_CR157","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41392-024-01827-y","volume":"9","author":"J Zimmer","year":"2024","unstructured":"Zimmer, J., Rolin, C. & Ollert, M. Two hits are better than one: rational dual strategy efficiently fights neuroblastoma. Signal Transduct. Target Ther. 9, 116 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR158","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","volume":"41","author":"E Bergaggio","year":"2023","unstructured":"Bergaggio, E. et al. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 41, 2100\u20132116.e2110 (2023).","journal-title":"Cancer Cell"},{"key":"2129_CR159","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.ccell.2023.11.009","volume":"41","author":"M Ruella","year":"2023","unstructured":"Ruella, M. ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma. Cancer Cell 41, 2016\u20132018 (2023).","journal-title":"Cancer Cell"},{"key":"2129_CR160","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41571-022-00643-z","volume":"19","author":"B Qiu","year":"2022","unstructured":"Qiu, B. & Matthay, K. K. Advancing therapy for neuroblastoma. Nat. Rev. Clin. Oncol. 19, 515\u2013533 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2129_CR161","doi-asserted-by":"publisher","unstructured":"Quamine, A. et al. TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant. bioRxiv https:\/\/doi.org\/10.1101\/2024.1107.1109.602731 (2024).","DOI":"10.1101\/2024.1107.1109.602731"},{"key":"2129_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49871-0","volume":"15","author":"JE Murray","year":"2024","unstructured":"Murray, J. E. et al. The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis. Nat. Commun. 15, 5585 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06791-7","volume":"15","author":"AS Pathania","year":"2024","unstructured":"Pathania, A. S. et al. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma. Cell Death Dis. 15, 428 (2024).","journal-title":"Cell Death Dis."},{"key":"2129_CR164","doi-asserted-by":"publisher","first-page":"1336031","DOI":"10.3389\/fonc.2024.1336031","volume":"14","author":"JC Jacobson","year":"2024","unstructured":"Jacobson, J. C., Qiao, J., Cochran, E. D., McCreery, S. & Chung, D. H. Migration, invasion, and metastasis are mediated by P-Rex1 in neuroblastoma. Front. Oncol. 14, 1336031 (2024).","journal-title":"Front. Oncol."},{"key":"2129_CR165","doi-asserted-by":"publisher","first-page":"110384","DOI":"10.1016\/j.radonc.2024.110384","volume":"198","author":"KX Liu","year":"2024","unstructured":"Liu, K. X. et al. Patterns of recurrence after radiotherapy for high-risk neuroblastoma: implications for radiation dose and field. Radiother. Oncol. 198, 110384 (2024).","journal-title":"Radiother. Oncol."},{"key":"2129_CR166","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00713","volume":"8","author":"CSC Vince","year":"2024","unstructured":"Vince, C. S. C. et al. Beyond clinical trials: understanding neurotrophic tropomyosin receptor kinase inhibitor challenges and efficacy in real-world pediatric oncology. JCO Precis. Oncol. 8, e2300713 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"2129_CR167","doi-asserted-by":"publisher","first-page":"eadh9547","DOI":"10.1126\/sciadv.adh9547","volume":"10","author":"X Qin","year":"2024","unstructured":"Qin, X. et al. CKLF instigates a \u201ccold\u201d microenvironment to promote MYCN-mediated tumor aggressiveness. Sci. Adv. 10, eadh9547 (2024).","journal-title":"Sci. Adv."},{"key":"2129_CR168","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3892\/or.2023.8603","volume":"50","author":"M Lukoseviciute","year":"2023","unstructured":"Lukoseviciute, M. et al. Efficacy of combined targeted therapy with PI3K and CDK4\/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines. Oncol. Rep. 50, 166 (2023).","journal-title":"Oncol. Rep."},{"key":"2129_CR169","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1158\/0008-5472.CAN-22-1913","volume":"83","author":"F Broso","year":"2023","unstructured":"Broso, F. et al. Alpha-1 adrenergic antagonists Sensitize neuroblastoma to therapeutic differentiation. Cancer Res. 83, 2733\u20132749 (2023).","journal-title":"Cancer Res."},{"key":"2129_CR170","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/2767-9764.CRC-21-0019","volume":"2","author":"A Castell","year":"2022","unstructured":"Castell, A. et al. MYCMI-7: a small MYC-binding compound that inhibits MYC: MAX interaction and tumor growth in a MYC-dependent manner. Cancer Res. Commun. 2, 182\u2013201 (2022).","journal-title":"Cancer Res. Commun."},{"key":"2129_CR171","doi-asserted-by":"publisher","unstructured":"Albiach, A. M. et al. Glioblastoma is spatially organized by neurodevelopmental programs and a glial-like wound healing response. bioRxiv https:\/\/doi.org\/10.1101\/2023.1109.1101.555882 (2023).","DOI":"10.1101\/2023.1109.1101.555882"},{"key":"2129_CR172","doi-asserted-by":"publisher","first-page":"110064","DOI":"10.1016\/j.isci.2024.110064","volume":"27","author":"X Lv","year":"2024","unstructured":"Lv, X. et al. Decoding heterogeneous and coordinated tissue architecture in glioblastoma using spatial transcriptomics. iScience 27, 110064 (2024).","journal-title":"iScience"},{"key":"2129_CR173","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","volume":"39","author":"T Hara","year":"2021","unstructured":"Hara, T. et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 39, 779\u2013792.e711 (2021).","journal-title":"Cancer Cell"},{"key":"2129_CR174","unstructured":"Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W. K. WHO Classification of Tumours of the Central Nervous System Revised 4th edn, Vol. 1 (IARC, 2016)."},{"key":"2129_CR175","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","volume":"32","author":"Q Wang","year":"2017","unstructured":"Wang, Q. et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32, 42\u201356.e46 (2017).","journal-title":"Cancer Cell"},{"key":"2129_CR176","doi-asserted-by":"publisher","first-page":"2002015","DOI":"10.1002\/advs.202002015","volume":"7","author":"Z Azam","year":"2020","unstructured":"Azam, Z., To, S. T. & Tannous, B. A. Mesenchymal transformation: the Rosetta Stone of glioblastoma pathogenesis and therapy resistance. Adv. Sci. 7, 2002015 (2020).","journal-title":"Adv. Sci."},{"key":"2129_CR177","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1101\/gad.12.23.3675","volume":"12","author":"EC Holland","year":"1998","unstructured":"Holland, E. C., Hively, W. P., DePinho, R. A. & Varmus, H. E. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 12, 3675\u20133685 (1998).","journal-title":"Genes Dev."},{"key":"2129_CR178","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1038\/s41388-020-1199-2","volume":"39","author":"R Yang","year":"2020","unstructured":"Yang, R. et al. EGFR activates GDH1 transcription to promote glutamine metabolism through MEK\/ERK\/ELK1 pathway in glioblastoma. Oncogene 39, 2975\u20132986 (2020).","journal-title":"Oncogene"},{"key":"2129_CR179","unstructured":"Heady, D. New drug delays progression of glioma, a deadly brain cancer. https:\/\/www.uclahealth.org\/news\/release\/new-drug-delays-progression-glioma-deadly-brain-cancer (2023)."},{"key":"2129_CR180","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med. 389, 589\u2013601 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2129_CR181","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"2129_CR182","unstructured":"Penn Medicine. \u201cDual-Target\u201d cell therapy appears to shrink brain tumors, Penn Medicine research finds. https:\/\/www.pennmedicine.org\/news\/news-releases\/2024\/march\/dual-target-cell-therapy-appears-to-shrink-brain-tumors (2024)."},{"key":"2129_CR183","unstructured":"National Cancer Institute. Powerful drug combination kills glioblastoma tumors containing a unique genetic makeup. https:\/\/ccr.cancer.gov\/neuro-oncology-branch\/powerful-drug-combination-kills-glioblastoma-tumors-containing-a-unique-genetic-makeup (2023)."},{"key":"2129_CR184","unstructured":"Drugs.com. Medications for glioblastoma multiforme. https:\/\/www.drugs.com\/condition\/glioblastoma-multiforme.html (2024)."},{"key":"2129_CR185","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.ccell.2024.06.004","volume":"42","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Multi-scale signaling and tumor evolution in high-grade gliomas. Cancer Cell 42, 1217\u20131238.e1219 (2024).","journal-title":"Cancer Cell"},{"key":"2129_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06769-5","volume":"15","author":"SM Joruiz","year":"2024","unstructured":"Joruiz, S. M., Von Muhlinen, N., Horikawa, I., Gilbert, M. R. & Harris, C. C. Distinct functions of wild-type and R273H mutant Delta133p53alpha differentially regulate glioblastoma aggressiveness and therapy-induced senescence. Cell Death Dis. 15, 454 (2024).","journal-title":"Cell Death Dis."},{"key":"2129_CR187","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-023-01666-3","volume":"8","author":"J Qu","year":"2023","unstructured":"Qu, J. et al. The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling. Signal Transduct. Target Ther. 8, 424 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR188","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.3390\/molecules29133095","volume":"29","author":"D Abu Rabe","year":"2024","unstructured":"Abu Rabe, D. et al. Identification of novel GANT61 analogs with activity in Hedgehog functional assays and GLI1-dependent cancer cells. Molecules 29, 3095 (2024).","journal-title":"Molecules"},{"key":"2129_CR189","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/cells13131086","volume":"13","author":"SA Schaufelberger","year":"2024","unstructured":"Schaufelberger, S. A. et al. 2-Methoxyestradiol, an endogenous 17beta-estradiol metabolite, induces antimitogenic and apoptotic actions in oligodendroglial precursor cells and triggers endoreduplication via the p53 pathway. Cells 13, 1086 (2024).","journal-title":"Cells"},{"key":"2129_CR190","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0074-7696(08)60391-5","volume":"94","author":"W Nagl","year":"1985","unstructured":"Nagl, W. Chromatin organization and the control of gene activity. Int. Rev. Cytol. 94, 21\u201356 (1985).","journal-title":"Int. Rev. Cytol."},{"key":"2129_CR191","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175033","volume":"134","author":"H Najem","year":"2024","unstructured":"Najem, H. et al. STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma. J. Clin. Invest. 134, e175033 (2024).","journal-title":"J. Clin. Invest."},{"key":"2129_CR192","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-021-00855-2","volume":"7","author":"QJ Gai","year":"2022","unstructured":"Gai, Q. J. et al. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct. Target Ther. 7, 33 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49989-1","volume":"15","author":"CA von Roemeling","year":"2024","unstructured":"von Roemeling, C. A. et al. Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade. Nat. Commun. 15, 5871 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR194","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00262-024-03770-x","volume":"73","author":"JRD Pearson","year":"2024","unstructured":"Pearson, J. R. D. et al. TRP-2\/gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors. Cancer Immunol. Immunother. 73, 178 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"2129_CR195","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMc2405721","volume":"390","author":"ER Gerstner","year":"2024","unstructured":"Gerstner, E. R., Choi, B. D. & Curry, W. T. Infusion of CARv3-TEAM-E T cells in glioblastoma. Reply. N. Engl. J. Med. 390, 2330\u20132331 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2129_CR196","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMc2405721","volume":"390","author":"ET Wong","year":"2024","unstructured":"Wong, E. T. Infusion of CARv3-TEAM-E T cells in glioblastoma. N. Engl. J. Med. 390, 2330 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2129_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107620","volume":"150","author":"M Han","year":"2024","unstructured":"Han, M. et al. Targeting MDM2-p53 interaction in glioblastoma: transcriptomic analysis and peptide-based inhibition strategy. Bioorg. Chem. 150, 107620 (2024).","journal-title":"Bioorg. Chem."},{"key":"2129_CR198","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.21873\/anticanres.17106","volume":"44","author":"Y Uemichi","year":"2024","unstructured":"Uemichi, Y. et al. Effects of lomerizine and its metabolite on glioblastoma cells. Anticancer Res. 44, 2943\u20132952 (2024).","journal-title":"Anticancer Res."},{"key":"2129_CR199","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/cells13120998","volume":"13","author":"E Ter Linden","year":"2024","unstructured":"Ter Linden, E., Abels, E. R., van Solinge, T. S., Neefjes, J. & Broekman, M. L. D. Overcoming barriers in glioblastoma-advances in drug delivery strategies. Cells 13, 998 (2024).","journal-title":"Cells"},{"key":"2129_CR200","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/01913123.2024.2371821","volume":"48","author":"G Tanriverdi","year":"2024","unstructured":"Tanriverdi, G. et al. The effects of the combination of temozolomide and Eribulin on T98G human glioblastoma cell line: an ultrastructural study. Ultrastruct. Pathol. 48, 323\u2013337 (2024).","journal-title":"Ultrastruct. Pathol."},{"key":"2129_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/srep28668","volume":"6","author":"N Tuncbag","year":"2016","unstructured":"Tuncbag, N. et al. Network modeling identifies patient-specific pathways in glioblastoma. Sci. Rep. 6, 28668 (2016).","journal-title":"Sci. Rep."},{"key":"2129_CR202","doi-asserted-by":"publisher","first-page":"e1006789","DOI":"10.1371\/journal.pcbi.1006789","volume":"15","author":"C Dincer","year":"2019","unstructured":"Dincer, C., Kaya, T., Keskin, O., Gursoy, A. & Tuncbag, N. 3D spatial organization and network-guided comparison of mutation profiles in Glioblastoma reveals similarities across patients. PLoS Comput. Biol. 15, e1006789 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"2129_CR203","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","volume":"187","author":"R Mathur","year":"2024","unstructured":"Mathur, R. et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell 187, 446\u2013463 (2024).","journal-title":"Cell"},{"key":"2129_CR204","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","volume":"42","author":"D Eisenbarth","year":"2023","unstructured":"Eisenbarth, D. & Wang, Y. A. Glioblastoma heterogeneity at single cell resolution. Oncogene 42, 2155\u20132165 (2023).","journal-title":"Oncogene"},{"key":"2129_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48053-2","volume":"15","author":"T Xie","year":"2024","unstructured":"Xie, T. et al. Pervasive structural heterogeneity rewires glioblastoma chromosomes to sustain patient-specific transcriptional programs. Nat. Commun. 15, 3905 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR206","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jcmgh.2021.11.010","volume":"13","author":"E Backx","year":"2022","unstructured":"Backx, E. et al. On the origin of pancreatic cancer: molecular tumor subtypes in perspective of exocrine cell plasticity. Cell Mol. Gastroenterol. Hepatol. 13, 1243\u20131253 (2022).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"2129_CR207","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","volume":"48","author":"J Luo","year":"2021","unstructured":"Luo, J. KRAS mutation in pancreatic cancer. Semin. Oncol. 48, 10\u201318 (2021).","journal-title":"Semin. Oncol."},{"key":"2129_CR208","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1042\/BST20170521","volume":"47","author":"S Lanfredini","year":"2019","unstructured":"Lanfredini, S., Thapa, A. & O\u2019Neill, E. RAS in pancreatic cancer. Biochem. Soc. Trans. 47, 961\u2013972 (2019).","journal-title":"Biochem. Soc. Trans."},{"key":"2129_CR209","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/MPA.0000000000000161","volume":"43","author":"BG Hassid","year":"2014","unstructured":"Hassid, B. G. et al. Absence of pancreatic intraepithelial neoplasia predicts poor survival after resection of pancreatic cancer. Pancreas 43, 1073\u20131077 (2014).","journal-title":"Pancreas"},{"key":"2129_CR210","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi, G. et al. IL1-induced JAK\/STAT signaling is antagonized by TGFbeta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282\u2013301 (2019).","journal-title":"Cancer Discov."},{"key":"2129_CR211","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/MPA.0000000000000867","volume":"46","author":"MT Salcedo Allende","year":"2017","unstructured":"Salcedo Allende, M. T. et al. Overexpression of yes associated protein 1, an independent prognostic marker in patients with pancreatic ductal adenocarcinoma, correlated with liver metastasis and poor prognosis. Pancreas 46, 913\u2013920 (2017).","journal-title":"Pancreas"},{"key":"2129_CR212","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ccell.2018.02.003","volume":"33","author":"J Andricovich","year":"2018","unstructured":"Andricovich, J. et al. Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. Cancer Cell 33, 512\u2013526.e518 (2018).","journal-title":"Cancer Cell"},{"key":"2129_CR213","first-page":"1613","volume":"71","author":"S Revia","year":"2022","unstructured":"Revia, S. et al. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer. Gut 71, 1613\u20131628 (2022).","journal-title":"Gut"},{"key":"2129_CR214","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495\u2013501 (2015).","journal-title":"Nature"},{"key":"2129_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8686","volume":"6","author":"M Sausen","year":"2015","unstructured":"Sausen, M. et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat. Commun. 6, 7686 (2015).","journal-title":"Nat. Commun."},{"key":"2129_CR216","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1126\/science.1149042","volume":"318","author":"MG Lee","year":"2007","unstructured":"Lee, M. G. et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 318, 447\u2013450 (2007).","journal-title":"Science"},{"key":"2129_CR217","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1136\/gut.2009.180711","volume":"58","author":"P Fritsche","year":"2009","unstructured":"Fritsche, P. et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58, 1399\u20131409 (2009).","journal-title":"Gut"},{"key":"2129_CR218","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1136\/gutjnl-2011-300060","volume":"61","author":"A Aghdassi","year":"2012","unstructured":"Aghdassi, A. et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61, 439\u2013448 (2012).","journal-title":"Gut"},{"key":"2129_CR219","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.cell.2016.04.033","volume":"165","author":"S Kugel","year":"2016","unstructured":"Kugel, S. et al. SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell 165, 1401\u20131415 (2016).","journal-title":"Cell"},{"key":"2129_CR220","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/15384047.2021.2017223","volume":"23","author":"M Ala","year":"2022","unstructured":"Ala, M. Target c-Myc to treat pancreatic cancer. Cancer Biol. Ther. 23, 34\u201350 (2022).","journal-title":"Cancer Biol. Ther."},{"key":"2129_CR221","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran, R. et al. The MYC oncogene\u2014the grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 19, 23\u201336 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2129_CR222","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927\u2013936 (2024).","journal-title":"Nature"},{"key":"2129_CR223","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.21873\/anticanres.13474","volume":"39","author":"D Ansari","year":"2019","unstructured":"Ansari, D. et al. The hippo signaling pathway in pancreatic cancer. Anticancer Res. 39, 3317\u20133321 (2019).","journal-title":"Anticancer Res."},{"key":"2129_CR224","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.7150\/thno.53438","volume":"11","author":"W Mao","year":"2021","unstructured":"Mao, W., Mai, J., Peng, H., Wan, J. & Sun, T. YAP in pancreatic cancer: oncogenic role and therapeutic strategy. Theranostics 11, 1753\u20131762 (2021).","journal-title":"Theranostics"},{"key":"2129_CR225","unstructured":"National Cancer Institute. Drugs approved for pancreatic cancer. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/pancreatic (2024)."},{"key":"2129_CR226","doi-asserted-by":"publisher","first-page":"e7345","DOI":"10.1002\/cam4.7345","volume":"13","author":"G Giordano","year":"2024","unstructured":"Giordano, G. et al. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Cancer Med. 13, e7345 (2024).","journal-title":"Cancer Med."},{"key":"2129_CR227","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-020-0168-0","volume":"5","author":"MZ Lei","year":"2020","unstructured":"Lei, M. Z. et al. Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth. Signal Transduct. Target Ther. 5, 70 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR228","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-024-01800-9","volume":"9","author":"S Zhang","year":"2024","unstructured":"Zhang, S., Yu, Q., Li, Z., Zhao, Y. & Sun, Y. Protein neddylation and its role in health and diseases. Signal Transduct. Target Ther. 9, 85 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR229","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-017-0005-2","volume":"3","author":"E Rozengurt","year":"2018","unstructured":"Rozengurt, E., Sinnett-Smith, J. & Eibl, G. Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival. Signal Transduct. Target Ther. 3, 11 (2018).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR230","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41392-023-01662-7","volume":"8","author":"G Wolters-Eisfeld","year":"2023","unstructured":"Wolters-Eisfeld, G., Hackert, T. & Gungor, C. Unmasking metabolic dependencies in pancreatic cancer: aberrant polyamine synthesis as a promising new therapeutic target. Signal Transduct. Target Ther. 8, 410 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48700-8","volume":"15","author":"M De Zuani","year":"2024","unstructured":"De Zuani, M. et al. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat. Commun. 15, 4388 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18632\/oncoscience.593","volume":"11","author":"MV Blagosklonny","year":"2024","unstructured":"Blagosklonny, M. V. My battle with cancer. Part 1. Oncoscience 11, 1\u201314 (2024).","journal-title":"Oncoscience"},{"key":"2129_CR233","doi-asserted-by":"publisher","first-page":"585284","DOI":"10.3389\/fonc.2020.585284","volume":"10","author":"T Zhu","year":"2020","unstructured":"Zhu, T. et al. Mechanisms and future of non-small cell lung cancer metastasis. Front. Oncol. 10, 585284 (2020).","journal-title":"Front. Oncol."},{"key":"2129_CR234","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihimaki","year":"2014","unstructured":"Riihimaki, M. et al. Metastatic sites and survival in lung cancer. Lung Cancer 86, 78\u201384 (2014).","journal-title":"Lung Cancer"},{"key":"2129_CR235","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33365-y","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis. Nat. Commun. 13, 5983 (2022).","journal-title":"Nat. Commun."},{"key":"2129_CR236","first-page":"256","volume":"4","author":"W Liu","year":"2014","unstructured":"Liu, W. et al. Protein signature for non-small cell lung cancer prognosis. Am. J. Cancer Res. 4, 256\u2013269 (2014).","journal-title":"Am. J. Cancer Res."},{"key":"2129_CR237","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41417-024-00761-z","volume":"31","author":"H Liang","year":"2024","unstructured":"Liang, H., Xu, Y., Zhao, J., Chen, M. & Wang, M. Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers. Cancer Gene Ther. 31, 652\u2013666 (2024).","journal-title":"Cancer Gene Ther."},{"key":"2129_CR238","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.3390\/cancers15153980","volume":"15","author":"N Choudhary","year":"2023","unstructured":"Choudhary, N. et al. Targeting cell signaling pathways in lung cancer by bioactive phytocompounds. Cancers 15, 3980 (2023).","journal-title":"Cancers"},{"key":"2129_CR239","doi-asserted-by":"publisher","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","volume":"1","author":"A Amatu","year":"2016","unstructured":"Amatu, A., Sartore-Bianchi, A. & Siena, S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1, e000023 (2016).","journal-title":"ESMO Open"},{"key":"2129_CR240","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","volume":"5","author":"A Vaishnavi","year":"2015","unstructured":"Vaishnavi, A., Le, A. T. & Doebele, R. C. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 5, 25\u201334 (2015).","journal-title":"Cancer Discov."},{"key":"2129_CR241","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863043","volume":"12","author":"N Yan","year":"2022","unstructured":"Yan, N. et al. BRAF-mutated non-small cell lung cancer: current treatment status and future perspective. Front. Oncol. 12, 863043 (2022).","journal-title":"Front. Oncol."},{"key":"2129_CR242","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.29825","volume":"138","author":"JS Ross","year":"2016","unstructured":"Ross, J. S. et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int. J. Cancer 138, 881\u2013890 (2016).","journal-title":"Int. J. Cancer"},{"key":"2129_CR243","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med."},{"key":"2129_CR244","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M. & Watson, I. R. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 37, 3183\u20133199 (2018).","journal-title":"Oncogene"},{"key":"2129_CR245","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1158\/2159-8290.CD-16-0075","volume":"6","author":"K Konduri","year":"2016","unstructured":"Konduri, K. et al. EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discov. 6, 601\u2013611 (2016).","journal-title":"Cancer Discov."},{"key":"2129_CR246","doi-asserted-by":"publisher","first-page":"497","DOI":"10.21037\/tlcr-21-888","volume":"11","author":"A Di Federico","year":"2022","unstructured":"Di Federico, A. et al. EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature. Transl. Lung Cancer Res. 11, 497\u2013503 (2022).","journal-title":"Transl. Lung Cancer Res."},{"key":"2129_CR247","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.hoc.2016.08.012","volume":"31","author":"KC Arbour","year":"2017","unstructured":"Arbour, K. C. & Riely, G. J. Diagnosis and treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Hematol. Oncol. Clin. North Am. 31, 101\u2013111 (2017).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"2129_CR248","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","volume":"9","author":"X Du","year":"2018","unstructured":"Du, X., Shao, Y., Qin, H. F., Tai, Y. H. & Gao, H. J. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac. Cancer 9, 423\u2013430 (2018).","journal-title":"Thorac. Cancer"},{"key":"2129_CR249","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/jpm12101651","volume":"12","author":"C Bontoux","year":"2022","unstructured":"Bontoux, C. et al. Deciphering the impact of HER2 alterations on non-small-cell lung cancer: from biological mechanisms to therapeutic approaches. J. Pers. Med. 12, 1651 (2022).","journal-title":"J. Pers. Med."},{"key":"2129_CR250","doi-asserted-by":"publisher","first-page":"1360492","DOI":"10.3389\/fonc.2024.1360492","volume":"14","author":"R Pishdad","year":"2024","unstructured":"Pishdad, R., Illei, P. B., Gocke, C. D. & Ball, D. W. RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report. Front. Oncol. 14, 1360492 (2024).","journal-title":"Front. Oncol."},{"key":"2129_CR251","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.3390\/cancers15194779","volume":"15","author":"G Spitaleri","year":"2023","unstructured":"Spitaleri, G. et al. MET in non-small-cell lung cancer (NSCLC): cross \u2018a Long and Winding Road\u2019 looking for a target. Cancers 15, 4779 (2023).","journal-title":"Cancers"},{"key":"2129_CR252","doi-asserted-by":"crossref","unstructured":"Blaquier, J. B. & Recondo, G. Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease. Drugs Context 11, 2022-2-2 (2022).","DOI":"10.7573\/dic.2022-2-2"},{"key":"2129_CR253","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/1878-0261.13397","volume":"17","author":"M Fernandes","year":"2023","unstructured":"Fernandes, M. et al. MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice. Mol. Oncol. 17, 2257\u20132274 (2023).","journal-title":"Mol. Oncol."},{"key":"2129_CR254","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","volume":"22","author":"JH Tong","year":"2016","unstructured":"Tong, J. H. et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin. Cancer Res. 22, 3048\u20133056 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2129_CR255","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154943","volume":"132","author":"MR Waarts","year":"2022","unstructured":"Waarts, M. R., Stonestrom, A. J., Park, Y. C. & Levine, R. L. Targeting mutations in cancer. J. Clin. Invest. 132, e154943 (2022).","journal-title":"J. Clin. Invest."},{"key":"2129_CR256","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1126\/science.aat7171","volume":"361","author":"JG Reiter","year":"2018","unstructured":"Reiter, J. G. et al. Minimal functional driver gene heterogeneity among untreated metastases. Science 361, 1033\u20131037 (2018).","journal-title":"Science"},{"key":"2129_CR257","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41416-021-01558-9","volume":"125","author":"A Martinez-Marti","year":"2021","unstructured":"Martinez-Marti, A. et al. Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. Br. J. Cancer 125, 1561\u20131569 (2021).","journal-title":"Br. J. Cancer"},{"key":"2129_CR258","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919\u2013926 (2024).","journal-title":"Nature"},{"key":"2129_CR259","unstructured":"American Cancer Society. Targeted drug therapy for non-small cell lung cancer. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/treating-non-small-cell\/targeted-therapies.html (2024)."},{"key":"2129_CR260","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2129_CR261","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 389, 2125\u20132139 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2129_CR262","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-022-01150-4","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian, Y. et al. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer. Signal Transduct. Target Ther. 7, 346 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR263","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-020-0182-2","volume":"5","author":"Y Yuan","year":"2020","unstructured":"Yuan, Y. et al. miR-410 induces both epithelial-mesenchymal transition and radioresistance through activation of the PI3K\/mTOR pathway in non-small cell lung cancer. Signal Transduct. Target Ther. 5, 85 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR264","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12554-6","volume":"24","author":"T Yamaguchi","year":"2024","unstructured":"Yamaguchi, T. et al. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis. BMC Cancer 24, 842 (2024).","journal-title":"BMC Cancer"},{"key":"2129_CR265","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-024-01861-w","volume":"9","author":"H Xia","year":"2024","unstructured":"Xia, H. et al. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study. Signal Transduct. Target Ther. 9, 145 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2129_CR266","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50063-z","volume":"15","author":"H Kitai","year":"2024","unstructured":"Kitai, H. et al. Combined inhibition of KRAS(G12C) and mTORC1 kinase is synergistic in non-small cell lung cancer. Nat. Commun. 15, 6076 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR267","first-page":"22","volume":"11","author":"E Rahul","year":"2021","unstructured":"Rahul, E. et al. An updated account on molecular heterogeneity of acute leukemia. Am. J. Blood Res. 11, 22\u201343 (2021).","journal-title":"Am. J. Blood Res."},{"key":"2129_CR268","first-page":"131","volume":"13","author":"N Saki","year":"2011","unstructured":"Saki, N., Abroun, S., Farshdousti Hagh, M. & Asgharei, F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J. 13, 131\u2013136 (2011).","journal-title":"Cell J."},{"key":"2129_CR269","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45737-7","volume":"15","author":"W Jin","year":"2024","unstructured":"Jin, W. et al. Cellular hierarchy insights reveal leukemic stem-like cells and early death risk in acute promyelocytic leukemia. Nat. Commun. 15, 1423 (2024).","journal-title":"Nat. Commun."},{"key":"2129_CR270","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cancergencyto.2008.03.006","volume":"184","author":"S Abe","year":"2008","unstructured":"Abe, S., Ishikawa, I., Harigae, H. & Sugawara, T. A new complex translocation t(5;17;15)(q11;q21;q22) in acute promyelocytic leukemia. Cancer Genet. Cytogenet. 184, 44\u201347 (2008).","journal-title":"Cancer Genet. Cytogenet."},{"key":"2129_CR271","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3727\/096504019X15528367532612","volume":"27","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide. Oncol. Res. 27, 1035\u20131042 (2019).","journal-title":"Oncol. Res."},{"key":"2129_CR272","unstructured":"PDQ Pediatric Treatment Editorial Board. in PDQ Cancer Information Summaries (National Cancer Institute (US), 2002)."},{"key":"2129_CR273","doi-asserted-by":"publisher","first-page":"e914","DOI":"10.1097\/HS9.0000000000000914","volume":"7","author":"S Turkalj","year":"2023","unstructured":"Turkalj, S., Radtke, F. A. & Vyas, P. An overview of targeted therapies in acute myeloid leukemia. Hemasphere 7, e914 (2023).","journal-title":"Hemasphere"},{"key":"2129_CR274","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ccell.2018.08.018","volume":"34","author":"Y Sun","year":"2018","unstructured":"Sun, Y. et al. HOXA9 reprograms the enhancer landscape to promote leukemogenesis. Cancer Cell 34, 643\u2013658.e645 (2018).","journal-title":"Cancer Cell"},{"key":"2129_CR275","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13072-019-0318-1","volume":"12","author":"J Yu","year":"2019","unstructured":"Yu, J. et al. Reduced H3K27me3 leads to abnormal Hox gene expression in neural tube defects. Epigenetics Chromatin 12, 76 (2019).","journal-title":"Epigenetics Chromatin"},{"key":"2129_CR276","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/onc.2015.174","volume":"35","author":"CT Collins","year":"2016","unstructured":"Collins, C. T. & Hess, J. L. Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Oncogene 35, 1090\u20131098 (2016).","journal-title":"Oncogene"},{"key":"2129_CR277","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.3390\/cancers12102792","volume":"12","author":"P Das","year":"2020","unstructured":"Das, P. & Taube, J. H. Regulating methylation at H3K27: a trick or treat for cancer cell plasticity. Cancers 12, 2792 (2020).","journal-title":"Cancers"},{"key":"2129_CR278","doi-asserted-by":"publisher","first-page":"194548","DOI":"10.1016\/j.bbagrm.2020.194548","volume":"1863","author":"S Takahashi","year":"2020","unstructured":"Takahashi, S. & Yokoyama, A. The molecular functions of common and atypical MLL fusion protein complexes. Biochim. Biophys. Acta Gene Regul. Mech. 1863, 194548 (2020).","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"2129_CR279","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33663-5","volume":"13","author":"E Kuijk","year":"2022","unstructured":"Kuijk, E., Kranenburg, O., Cuppen, E. & Van Hoeck, A. Common anti-cancer therapies induce somatic mutations in stem cells of healthy tissue. Nat. Commun. 13, 5915 (2022).","journal-title":"Nat. Commun."},{"key":"2129_CR280","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41586-024-07410-3","volume":"630","author":"Q Luo","year":"2024","unstructured":"Luo, Q. et al. Targetable leukaemia dependency on noncanonical PI3Kgamma signalling. Nature 630, 198\u2013205 (2024).","journal-title":"Nature"},{"key":"2129_CR281","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.gendis.2023.01.008","volume":"11","author":"S Azizidoost","year":"2024","unstructured":"Azizidoost, S. et al. Signaling pathways governing the behaviors of leukemia stem cells. Genes Dis. 11, 830\u2013846 (2024).","journal-title":"Genes Dis."},{"key":"2129_CR282","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10020-024-00861-4","volume":"30","author":"X Tan","year":"2024","unstructured":"Tan, X. et al. The dual role of FSP1 in programmed cell death: resisting ferroptosis in the cell membrane and promoting necroptosis in the nucleus of THP-1 cells. Mol. Med. 30, 102 (2024).","journal-title":"Mol. Med."},{"key":"2129_CR283","doi-asserted-by":"publisher","first-page":"104424","DOI":"10.1016\/j.critrevonc.2024.104424","volume":"201","author":"M Ruglioni","year":"2024","unstructured":"Ruglioni, M. et al. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. Crit. Rev. Oncol. Hematol. 201, 104424 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2129_CR284","doi-asserted-by":"publisher","unstructured":"Herrero Alvarez, N. et al. (89)Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia. Eur. J. Nucl. Med. Mol. Imaging. https:\/\/doi.org\/10.1007\/s00259-00024-06814-00257 (2024).","DOI":"10.1007\/s00259-00024-06814-00257"},{"key":"2129_CR285","doi-asserted-by":"publisher","first-page":"10795","DOI":"10.1021\/acs.jmedchem.4c00291","volume":"67","author":"J Lou","year":"2024","unstructured":"Lou, J. et al. Discovery of a covalent inhibitor that overcame resistance to venetoclax in AML cells overexpressing BFL-1. J. Med. Chem. 67, 10795\u201310830 (2024).","journal-title":"J. Med. Chem."},{"key":"2129_CR286","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-10-11","volume":"10","author":"SS Knox","year":"2010","unstructured":"Knox, S. S. From \u2018omics\u2019 to complex disease: a systems biology approach to gene-environment interactions in cancer. Cancer Cell Int. 10, 11 (2010).","journal-title":"Cancer Cell Int."},{"key":"2129_CR287","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0092-8674(02)00622-0","volume":"108","author":"A Balmain","year":"2002","unstructured":"Balmain, A. Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell 108, 145\u2013152 (2002).","journal-title":"Cell"},{"key":"2129_CR288","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-6-4","volume":"6","author":"F Grizzi","year":"2006","unstructured":"Grizzi, F. & Chiriva-Internati, M. Cancer: looking for simplicity and finding complexity. Cancer Cell Int. 6, 4 (2006).","journal-title":"Cancer Cell Int."},{"key":"2129_CR289","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","volume":"187","author":"C Swanton","year":"2024","unstructured":"Swanton, C. et al. Embracing cancer complexity: hallmarks of systemic disease. Cell 187, 1589\u20131616 (2024).","journal-title":"Cell"},{"key":"2129_CR290","unstructured":"National Cancer Institute. BRCA gene mutations: cancer risk and genetic testing. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet (2020)."},{"key":"2129_CR291","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/annonc\/mdv022","volume":"26","author":"S Shiovitz","year":"2015","unstructured":"Shiovitz, S. & Korde, L. A. Genetics of breast cancer: a topic in evolution. Ann. Oncol. 26, 1291\u20131299 (2015).","journal-title":"Ann. Oncol."},{"key":"2129_CR292","unstructured":"Petrucelli, N., Daly, M. B. & Pal, T. in GeneReviews (eds Adam, M. P., Feldman, J. & Mirzaa, G. M.) (University of Washington, 2023)."},{"key":"2129_CR293","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"Breast Cancer Association, C.","year":"2021","unstructured":"Breast Cancer Association, C. et al. Breast cancer risk genes\u2014association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428\u2013439 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2129_CR294","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch, P. D. et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J. Clin. Oncol. 37, 453\u2013460 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2129_CR295","unstructured":"National Cancer Institute. Genetics of Colorectal Cancer (PDQ\u00ae)\u2013Health Professional Version. https:\/\/www.cancer.gov\/types\/colorectal\/hp\/colorectal-genetics-pdq (2024)."},{"key":"2129_CR296","unstructured":"Medina Pab\u00f3n, M. A. & Babiker, H. M. in StatPearls (StatPearls Publishing, 2022)."},{"key":"2129_CR297","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.sbi.2015.01.004","volume":"32","author":"R Nussinov","year":"2015","unstructured":"Nussinov, R. & Tsai, C. J. \u2018Latent drivers\u2019 expand the cancer mutational landscape. Curr. Opin. Struct. Biol. 32, 25\u201332 (2015).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"2129_CR298","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12551-018-0496-2","volume":"11","author":"R Nussinov","year":"2019","unstructured":"Nussinov, R., Jang, H., Tsai, C. J. & Cheng, F. Precision medicine review: rare driver mutations and their biophysical classification. Biophys. Rev. 11, 5\u201319 (2019).","journal-title":"Biophys. Rev."},{"key":"2129_CR299","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr.","year":"1971","unstructured":"Knudson, A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820\u2013823 (1971).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2129_CR300","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/bjc.1969.41","volume":"23","author":"DJ Ashley","year":"1969","unstructured":"Ashley, D. J. The two \u201chit\u201d and multiple \u201chit\u201d theories of carcinogenesis. Br. J. Cancer 23, 313\u2013328 (1969).","journal-title":"Br. J. Cancer"},{"key":"2129_CR301","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/bjc.1953.8","volume":"7","author":"CO Nordling","year":"1953","unstructured":"Nordling, C. O. A new theory on cancer-inducing mechanism. Br. J. Cancer 7, 68\u201372 (1953).","journal-title":"Br. J. Cancer"},{"key":"2129_CR302","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00018-023-05052-8","volume":"81","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Zhang, W., Jang, H. & Nussinov, R. SHP2 clinical phenotype, cancer, or RASopathies, can be predicted by mutant conformational propensities. Cell Mol. Life Sci. 81, 5 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"2129_CR303","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1376639","volume":"12","author":"R Nussinov","year":"2024","unstructured":"Nussinov, R. et al. Review: Cancer and neurodevelopmental disorders: multi-scale reasoning and computational guide. Front. Cell Dev. Biol. 12, 1376639 (2024).","journal-title":"Front. Cell Dev. Biol."},{"key":"2129_CR304","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1039\/D3SC04690G","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Zhang, M., Jang, H. & Nussinov, R. The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization. Chem. Sci. 15, 1003\u20131017 (2024).","journal-title":"Chem. Sci."},{"key":"2129_CR305","doi-asserted-by":"publisher","first-page":"168354","DOI":"10.1016\/j.jmb.2023.168354","volume":"435","author":"H Jang","year":"2023","unstructured":"Jang, H., Chen, J., Iakoucheva, L. M. & Nussinov, R. Cancer and autism: how PTEN mutations degrade function at the membrane and isoform expression in the human brain. J. Mol. Biol. 435, 168354 (2023).","journal-title":"J. Mol. Biol."},{"key":"2129_CR306","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41525-023-00377-6","volume":"8","author":"BR Yavuz","year":"2023","unstructured":"Yavuz, B. R. et al. Neurodevelopmental disorders and cancer networks share pathways, but differ in mechanisms, signaling strength, and outcome. NPJ Genom. Med. 8, 37 (2023).","journal-title":"NPJ Genom. Med."},{"key":"2129_CR307","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12551-023-01054-9","volume":"15","author":"R Nussinov","year":"2023","unstructured":"Nussinov, R. et al. Neurodevelopmental disorders, like cancer, are connected to impaired chromatin remodelers, PI3K\/mTOR, and PAK1-regulated MAPK. Biophys. Rev. 15, 163\u2013181 (2023).","journal-title":"Biophys. Rev."},{"key":"2129_CR308","doi-asserted-by":"publisher","first-page":"104492","DOI":"10.1016\/j.isci.2022.104492","volume":"25","author":"R Nussinov","year":"2022","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. Neurodevelopmental disorders, immunity, and cancer are connected. iScience 25, 104492 (2022).","journal-title":"iScience"},{"key":"2129_CR309","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"2129_CR310","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2129_CR311","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.18632\/aging.204082","volume":"14","author":"MV Blagosklonny","year":"2022","unstructured":"Blagosklonny, M. V. Hallmarks of cancer and hallmarks of aging. Aging 14, 4176\u20134187 (2022).","journal-title":"Aging"},{"key":"2129_CR312","doi-asserted-by":"publisher","first-page":"1055589","DOI":"10.3389\/fonc.2022.1055589","volume":"12","author":"H Werner","year":"2022","unstructured":"Werner, H. & LeRoith, D. Hallmarks of cancer: the insulin-like growth factors perspective. Front. Oncol. 12, 1055589 (2022).","journal-title":"Front. Oncol."},{"key":"2129_CR313","first-page":"e24803","volume":"14","author":"S Ravi","year":"2022","unstructured":"Ravi, S. et al. An update to hallmarks of cancer. Cureus 14, e24803 (2022).","journal-title":"Cureus"},{"key":"2129_CR314","doi-asserted-by":"publisher","first-page":"101103","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano, A. et al. Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist. Updat. 76, 101103 (2024).","journal-title":"Drug Resist. Updat."},{"key":"2129_CR315","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.7150\/ijbs.92671","volume":"20","author":"R Sciarrillo","year":"2024","unstructured":"Sciarrillo, R. et al. Exploring splicing modulation as an innovative approach to combat pancreatic cancer: SF3B1 emerges as a prognostic indicator and therapeutic target. Int. J. Biol. Sci. 20, 3173\u20133184 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"2129_CR316","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1021\/jacsau.4c00138","volume":"4","author":"W Zhang","year":"2024","unstructured":"Zhang, W., Liu, Y., Jang, H. & Nussinov, R. CDK2 and CDK4: cell cycle functions evolve distinct, catalysis-competent conformations, offering drug targets. JACS Au 4, 1911\u20131927 (2024).","journal-title":"JACS Au"},{"key":"2129_CR317","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.devcel.2022.02.014","volume":"57","author":"I Burda","year":"2022","unstructured":"Burda, I. & Roeder, A. H. K. Stepping on the molecular brake: slowing down proliferation to allow differentiation. Dev. Cell 57, 561\u2013563 (2022).","journal-title":"Dev. Cell"},{"key":"2129_CR318","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/med.21863","volume":"42","author":"R Nussinov","year":"2022","unstructured":"Nussinov, R. et al. Mechanism of activation and the rewired network: new drug design concepts. Med. Res. Rev. 42, 770\u2013799 (2022).","journal-title":"Med. Res. Rev."},{"key":"2129_CR319","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0959-437X(00)00162-3","volume":"11","author":"L Zhu","year":"2001","unstructured":"Zhu, L. & Skoultchi, A. I. Coordinating cell proliferation and differentiation. Curr. Opin. Genet. Dev. 11, 91\u201397 (2001).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2129_CR320","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.tips.2017.02.001","volume":"38","author":"R Nussinov","year":"2017","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. A new view of pathway-driven drug resistance in tumor proliferation. Trends Pharm. Sci. 38, 427\u2013437 (2017).","journal-title":"Trends Pharm. Sci."},{"key":"2129_CR321","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.tibs.2020.03.013","volume":"45","author":"R Nussinov","year":"2020","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. Are parallel proliferation pathways redundant? Trends Biochem. Sci. 45, 554\u2013563 (2020).","journal-title":"Trends Biochem. Sci."},{"key":"2129_CR322","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41388-021-02076-x","volume":"41","author":"K Ingram","year":"2022","unstructured":"Ingram, K. et al. NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity. Oncogene 41, 293\u2013300 (2022).","journal-title":"Oncogene"},{"key":"2129_CR323","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.semcancer.2013.04.001","volume":"23","author":"CJ Tsai","year":"2013","unstructured":"Tsai, C. J. & Nussinov, R. The molecular basis of targeting protein kinases in cancer therapeutics. Semin. Cancer Biol. 23, 235\u2013242 (2013).","journal-title":"Semin. Cancer Biol."},{"key":"2129_CR324","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70494-0","volume":"10","author":"R Rasnic","year":"2020","unstructured":"Rasnic, R., Linial, N. & Linial, M. Expanding cancer predisposition genes with ultra-rare cancer-exclusive human variations. Sci. Rep. 10, 13462 (2020).","journal-title":"Sci. Rep."},{"key":"2129_CR325","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.tips.2019.10.003","volume":"40","author":"R Nussinov","year":"2019","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. Why are some driver mutations rare? Trends Pharm. Sci. 40, 919\u2013929 (2019).","journal-title":"Trends Pharm. Sci."},{"key":"2129_CR326","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/cpt.1938","volume":"108","author":"RA Beckman","year":"2020","unstructured":"Beckman, R. A. & Loeb, L. A. Rare mutations in cancer drug resistance and implications for therapy. Clin. Pharm. Ther. 108, 437\u2013439 (2020).","journal-title":"Clin. Pharm. Ther."},{"key":"2129_CR327","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gde.2019.02.004","volume":"54","author":"C Scholl","year":"2019","unstructured":"Scholl, C. & Frohling, S. Exploiting rare driver mutations for precision cancer medicine. Curr. Opin. Genet. Dev. 54, 1\u20136 (2019).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2129_CR328","doi-asserted-by":"publisher","first-page":"a019505","DOI":"10.1101\/cshperspect.a019505","volume":"8","author":"SB Baylin","year":"2016","unstructured":"Baylin, S. B. & Jones, P. A. Epigenetic determinants of cancer. Cold Spring Harb. Perspect. Biol. 8, a019505 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2129_CR329","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1042\/CS20210449","volume":"136","author":"JS Gray","year":"2022","unstructured":"Gray, J. S., Wani, S. A. & Campbell, M. J. Epigenomic alterations in cancer: mechanisms and therapeutic potential. Clin. Sci. 136, 473\u2013492 (2022).","journal-title":"Clin. Sci."},{"key":"2129_CR330","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"2129_CR331","doi-asserted-by":"publisher","first-page":"e1006648","DOI":"10.1371\/journal.pcbi.1006648","volume":"15","author":"R Nussinov","year":"2019","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. Protein ensembles link genotype to phenotype. PLoS Comput. Biol. 15, e1006648 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"2129_CR332","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/03009734.2012.659294","volume":"117","author":"A Jogi","year":"2012","unstructured":"Jogi, A., Vaapil, M., Johansson, M. & Pahlman, S. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Ups. J. Med Sci. 117, 217\u2013224 (2012).","journal-title":"Ups. J. Med Sci."},{"key":"2129_CR333","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1158\/2159-8290.CD-20-1637","volume":"11","author":"S Saghafinia","year":"2021","unstructured":"Saghafinia, S. et al. Cancer cells retrace a stepwise differentiation program during malignant progression. Cancer Discov. 11, 2638\u20132657 (2021).","journal-title":"Cancer Discov."},{"key":"2129_CR334","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.CD-23-0289","volume":"14","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. Cancer Discov. 14, 308\u2013325 (2024).","journal-title":"Cancer Discov."},{"key":"2129_CR335","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41518-w","volume":"14","author":"S Mayer","year":"2023","unstructured":"Mayer, S. et al. The tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts. Nat. Commun. 14, 5810 (2023).","journal-title":"Nat. Commun."},{"key":"2129_CR336","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","volume":"19","author":"CA Schmitt","year":"2022","unstructured":"Schmitt, C. A., Wang, B. & Demaria, M. Senescence and cancer\u2014role and therapeutic opportunities. Nat. Rev. Clin. Oncol. 19, 619\u2013636 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2129_CR337","doi-asserted-by":"publisher","first-page":"1189015","DOI":"10.3389\/fonc.2023.1189015","volume":"13","author":"S Xiao","year":"2023","unstructured":"Xiao, S. et al. Cellular senescence: a double-edged sword in cancer therapy. Front. Oncol. 13, 1189015 (2023).","journal-title":"Front. Oncol."},{"key":"2129_CR338","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/2159-8290.CD-22-0528","volume":"13","author":"HA Chen","year":"2023","unstructured":"Chen, H. A. et al. Senescence rewires microenvironment sensing to facilitate antitumor immunity. Cancer Discov. 13, 432\u2013453 (2023).","journal-title":"Cancer Discov."},{"key":"2129_CR339","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3892\/ol.2021.12757","volume":"22","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. Possibility of inducing tumor cell senescence during therapy. Oncol. Lett. 22, 496 (2021).","journal-title":"Oncol. Lett."},{"key":"2129_CR340","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41388-019-1110-1","volume":"39","author":"T Meirson","year":"2020","unstructured":"Meirson, T., Gil-Henn, H. & Samson, A. O. Invasion and metastasis: the elusive hallmark of cancer. Oncogene 39, 2024\u20132026 (2020).","journal-title":"Oncogene"},{"key":"2129_CR341","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-24-0097","volume":"14","author":"MP Alcolea","year":"2024","unstructured":"Alcolea, M. P. et al. Cancer hallmarks: piecing the puzzle together. Cancer Discov. 14, 674\u2013682 (2024).","journal-title":"Cancer Discov."},{"key":"2129_CR342","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/1758834014530023","volume":"6","author":"E Paplomata","year":"2014","unstructured":"Paplomata, E. & O\u2019Regan, R. The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther. Adv. Med. Oncol. 6, 154\u2013166 (2014).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2129_CR343","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A. et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138 (2023).","journal-title":"Mol. Cancer"},{"key":"2129_CR344","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng, Y., Wang, Y., Zhou, C., Mei, W. & Zeng, C. PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front. Oncol. 12, 819128 (2022).","journal-title":"Front. Oncol."},{"key":"2129_CR345","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.3390\/cancers15215297","volume":"15","author":"W Wiese","year":"2023","unstructured":"Wiese, W. et al. PI3K\/Akt\/mTOR signaling pathway in blood malignancies\u2014new therapeutic possibilities. Cancers 15, 5297 (2023).","journal-title":"Cancers"},{"key":"2129_CR346","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","volume":"13","author":"R Dienstmann","year":"2014","unstructured":"Dienstmann, R., Rodon, J., Serra, V. & Tabernero, J. Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors. Mol. Cancer Ther. 13, 1021\u20131031 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"2129_CR347","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","volume":"31","author":"HP Zhang","year":"2024","unstructured":"Zhang, H. P. et al. PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer 31, 539\u2013551 (2024).","journal-title":"Breast Cancer"},{"key":"2129_CR348","doi-asserted-by":"publisher","first-page":"628690","DOI":"10.3389\/fphar.2021.628690","volume":"12","author":"C Dong","year":"2021","unstructured":"Dong, C., Wu, J., Chen, Y., Nie, J. & Chen, C. Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer. Front. Pharm. 12, 628690 (2021).","journal-title":"Front. Pharm."},{"key":"2129_CR349","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2002","unstructured":"Zhang, W. & Liu, H. T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12, 9\u201318 (2002).","journal-title":"Cell Res."},{"key":"2129_CR350","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","volume":"75","author":"M Cargnello","year":"2011","unstructured":"Cargnello, M. & Roux, P. P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50\u201383 (2011).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"2129_CR351","first-page":"1997","volume":"19","author":"YJ Guo","year":"2020","unstructured":"Guo, Y. J. et al. ERK\/MAPK signalling pathway and tumorigenesis. Exp. Ther. Med. 19, 1997\u20132007 (2020).","journal-title":"Exp. Ther. Med."},{"key":"2129_CR352","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","volume":"13","author":"J Yuan","year":"2020","unstructured":"Yuan, J., Dong, X., Yap, J. & Hu, J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J. Hematol. Oncol. 13, 113 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2129_CR353","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3109\/10799893.2015.1030412","volume":"35","author":"Y Sun","year":"2015","unstructured":"Sun, Y. et al. Signaling pathway of MAPK\/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J. Recept Signal Transduct. Res. 35, 600\u2013604 (2015).","journal-title":"J. Recept Signal Transduct. Res."},{"key":"2129_CR354","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41556-022-00860-9","volume":"24","author":"G Gaglia","year":"2022","unstructured":"Gaglia, G. et al. Temporal and spatial topography of cell proliferation in cancer. Nat. Cell Biol. 24, 316\u2013326 (2022).","journal-title":"Nat. Cell Biol."},{"key":"2129_CR355","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00554-5","volume":"8","author":"O Timofeev","year":"2024","unstructured":"Timofeev, O., Giron, P., Lawo, S., Pichler, M. & Noeparast, M. ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework. NPJ Precis. Oncol. 8, 70 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"2129_CR356","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","volume":"19","author":"R Barbosa","year":"2021","unstructured":"Barbosa, R., Acevedo, L. A. & Marmorstein, R. The MEK\/ERK network as a therapeutic target in human cancer. Mol. Cancer Res. 19, 361\u2013374 (2021).","journal-title":"Mol. Cancer Res."},{"key":"2129_CR357","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1158\/2159-8290.CD-17-1355","volume":"8","author":"I Smalley","year":"2018","unstructured":"Smalley, I. & Smalley, K. S. M. ERK inhibition: a new front in the war against MAPK pathway-driven cancers? Cancer Discov. 8, 140\u2013142 (2018).","journal-title":"Cancer Discov."},{"key":"2129_CR358","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.3390\/cancers14194625","volume":"14","author":"Y Cheng","year":"2022","unstructured":"Cheng, Y., Chen, J., Shi, Y., Fang, X. & Tang, Z. MAPK signaling pathway in oral squamous cell carcinoma: biological function and targeted therapy. Cancers 14, 4625 (2022).","journal-title":"Cancers"},{"key":"2129_CR359","doi-asserted-by":"crossref","unstructured":"Numan, Y. et al. Chemokine signaling and MAPK\/ERK pathway for advanced prostate cancer treatment response: in ASCO Annual Meeting. J Clin. Oncol. 38, TPS275 (2020).","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS275"},{"key":"2129_CR360","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coisb.2016.12.003","volume":"1","author":"YE Antebi","year":"2017","unstructured":"Antebi, Y. E., Nandagopal, N. & Elowitz, M. B. An operational view of intercellular signaling pathways. Curr. Opin. Syst. Biol. 1, 16\u201324 (2017).","journal-title":"Curr. Opin. Syst. Biol."},{"key":"2129_CR361","doi-asserted-by":"publisher","first-page":"109157","DOI":"10.1016\/j.celrep.2021.109157","volume":"35","author":"BN Kholodenko","year":"2021","unstructured":"Kholodenko, B. N., Rauch, N., Kolch, W. & Rukhlenko, O. S. A systematic analysis of signaling reactivation and drug resistance. Cell Rep. 35, 109157 (2021).","journal-title":"Cell Rep."},{"key":"2129_CR362","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3390\/genes12040553","volume":"12","author":"AA Nolan","year":"2021","unstructured":"Nolan, A. A., Aboud, N. K., Kolch, W. & Matallanas, D. Hidden targets in RAF signalling pathways to block oncogenic RAS signalling. Genes 12, 553 (2021).","journal-title":"Genes"},{"key":"2129_CR363","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: navigating the network. Cell 169, 381\u2013405 (2017).","journal-title":"Cell"},{"key":"2129_CR364","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tcb.2020.12.001","volume":"31","author":"M Kreileder","year":"2021","unstructured":"Kreileder, M., Barrett, I., Bendtsen, C., Brennan, D. & Kolch, W. Signaling dynamics regulating crosstalks between T-cell activation and immune checkpoints. Trends Cell Biol. 31, 224\u2013235 (2021).","journal-title":"Trends Cell Biol."},{"key":"2129_CR365","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1021\/acs.jpcb.1c00540","volume":"125","author":"WV Tee","year":"2021","unstructured":"Tee, W. V., Tan, Z. W., Lee, K., Guarnera, E. & Berezovsky, I. N. Exploring the allosteric territory of protein function. J. Phys. Chem. B 125, 3763\u20133780 (2021).","journal-title":"J. Phys. Chem. B"},{"key":"2129_CR366","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells10030659","volume":"10","author":"HYK Yip","year":"2021","unstructured":"Yip, H. Y. K. & Papa, A. Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments. Cells 10, 659 (2021).","journal-title":"Cells"},{"key":"2129_CR367","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1038\/s44318-024-00146-w","volume":"43","author":"W Magits","year":"2024","unstructured":"Magits, W. et al. K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins. EMBO J. 43, 2862\u20132877 (2024).","journal-title":"EMBO J."},{"key":"2129_CR368","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4982","volume":"33","author":"L Thines","year":"2024","unstructured":"Thines, L. et al. Disruption of Ca2+\/calmodulin: KSR1 interaction lowers ERK activation. Protein Sci. 33, e4982 (2024).","journal-title":"Protein Sci."},{"key":"2129_CR369","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303367","volume":"10","author":"RN Sewduth","year":"2023","unstructured":"Sewduth, R. N. et al. Spatial mechano-signaling regulation of GTPases through non-degradative ubiquitination. Adv. Sci. 10, e2303367 (2023).","journal-title":"Adv. Sci."},{"key":"2129_CR370","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-pharmtox-022823-113946","volume":"64","author":"R Nussinov","year":"2024","unstructured":"Nussinov, R. & Jang, H. Direct K-Ras inhibitors to treat cancers: progress, new insights, and approaches to treat resistance. Annu. Rev. Pharm. Toxicol. 64, 231\u2013253 (2024).","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"2129_CR371","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05434-z","volume":"13","author":"C Yi","year":"2022","unstructured":"Yi, C. et al. Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia. Cell Death Dis. 13, 1004 (2022).","journal-title":"Cell Death Dis."},{"key":"2129_CR372","doi-asserted-by":"crossref","unstructured":"Harvey, A. J. in Predictive Biomarkers in Oncology (eds Badve, S. & Kumar, G.) Ch. 12 Overview of Cell Signaling Pathways in Cancer, 167\u2013182 (Springer, Cham, 2019).","DOI":"10.1007\/978-3-319-95228-4_12"},{"key":"2129_CR373","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1535-6108(03)00216-2","volume":"4","author":"GS Martin","year":"2003","unstructured":"Martin, G. S. Cell signaling and cancer. Cancer Cell 4, 167\u2013174 (2003).","journal-title":"Cancer Cell"},{"key":"2129_CR374","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1615\/CritRevOncog.v20.i5-6.150","volume":"20","author":"Y Fontebasso","year":"2015","unstructured":"Fontebasso, Y. & Dubinett, S. M. Drug development for metastasis prevention. Crit. Rev. Oncog. 20, 449\u2013473 (2015).","journal-title":"Crit. Rev. Oncog."},{"key":"2129_CR375","doi-asserted-by":"publisher","first-page":"112560","DOI":"10.1016\/j.celrep.2023.112560","volume":"42","author":"DK Singh","year":"2023","unstructured":"Singh, D. K. et al. 5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-beta-SMAD4 signaling. Cell Rep. 42, 112560 (2023).","journal-title":"Cell Rep."},{"key":"2129_CR376","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh, K. & Massague, J. Targeting metastatic cancer. Nat. Med. 27, 34\u201344 (2021).","journal-title":"Nat. Med."},{"key":"2129_CR377","unstructured":"Albert Einstein College of Medicine. How an anti-metastasis drug combination works. https:\/\/einsteinmed.edu\/research-briefs\/11015\/how-an-anti-metastasis-drug-combination-works\/ (2023)."},{"key":"2129_CR378","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-018-0134-8","volume":"16","author":"RL Anderson","year":"2019","unstructured":"Anderson, R. L. et al. A framework for the development of effective anti-metastatic agents. Nat. Rev. Clin. Oncol. 16, 185\u2013204 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2129_CR379","unstructured":"National Cancer Institute. Experimental cancer drug metarrestin targets metastatic tumors. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/metaresstin-metastatic-tumors (2018)."},{"key":"2129_CR380","doi-asserted-by":"publisher","unstructured":"Schorghofer, D. et al. Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation. Br. J. Cancer https:\/\/doi.org\/10.1038\/s41416-41024-02758-41419 (2024).","DOI":"10.1038\/s41416-41024-02758-41419"},{"key":"2129_CR381","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4504","volume":"32","author":"Y Liu","year":"2023","unstructured":"Liu, Y., Zhang, M., Jang, H. & Nussinov, R. Higher-order interactions of Bcr-Abl can broaden chronic myeloid leukemia (CML) drug repertoire. Protein Sci. 32, e4504 (2023).","journal-title":"Protein Sci."},{"key":"2129_CR382","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1016\/j.csbj.2022.08.014","volume":"20","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Zhang, M., Tsai, C. J., Jang, H. & Nussinov, R. Allosteric regulation of autoinhibition and activation of c-Abl. Comput. Struct. Biotechnol. J. 20, 4257\u20134270 (2022).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"2129_CR383","unstructured":"National Cancer Institute. Drugs approved for neuroblastoma. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/neuroblastoma (2021)."},{"key":"2129_CR384","unstructured":"Inman, S. FDA approves dinutuximab for high-risk neuroblastoma. https:\/\/www.onclive.com\/view\/fda-approves-dinutuximab-for-high-risk-neuroblastoma (2015)."},{"key":"2129_CR385","unstructured":"National Cancer Institute. FDA approves first therapy for high-risk neuroblastoma. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2015\/dinutuximab-neuroblastoma (2015)."},{"key":"2129_CR386","unstructured":"FDA. FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow (2020)."},{"key":"2129_CR387","unstructured":"Serani, S. FDA\u2019S ODAC votes yes to eflornithine for pediatric neuroblastomas (2023)."},{"key":"2129_CR388","unstructured":"FDA. FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-eflornithine-adult-and-pediatric-patients-high-risk-neuroblastoma (2023)."},{"key":"2129_CR389","unstructured":"National Cancer Institute. Drugs approved for brain tumors. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/brain (2024)."},{"key":"2129_CR390","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/biomedicines9030324","volume":"9","author":"JP Fisher","year":"2021","unstructured":"Fisher, J. P. & Adamson, D. C. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines 9, 324 (2021).","journal-title":"Biomedicines"},{"key":"2129_CR391","unstructured":"Dana-Farber Cancer Institute. FDA approves new therapy for glioma patients for first time in decades. https:\/\/www.dana-farber.org\/newsroom\/news-releases\/2024\/fda-approves-new-therapy-for-glioma-patients-for-first-time-in-decades (2024)."},{"key":"2129_CR392","unstructured":"National Cancer Institute. Drugs approved for lung cancer. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/lung#1 (2024)."},{"key":"2129_CR393","unstructured":"National Cancer Institute. Drugs approved for leukemia. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/leukemia (2024)."},{"key":"2129_CR394","unstructured":"National Cancer Institute. Drugs approved for breast cancer. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/breast (2024)."},{"key":"2129_CR395","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2129_CR396","unstructured":"National Cancer Institute. Drugs approved for liver cancer. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/liver (2024)."},{"key":"2129_CR397","unstructured":"American Liver Foundation. Rare forms of liver cancer. https:\/\/liverfoundation.org\/resource-center\/blog\/rare-liver-disease-month-focus-rare-forms-of-liver-cancer\/ (2021)."},{"key":"2129_CR398","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41575-024-00934-z","volume":"21","author":"A Canellas-Socias","year":"2024","unstructured":"Canellas-Socias, A., Sancho, E. & Batlle, E. Mechanisms of metastatic colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 21, 609\u2013625 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2129_CR399","unstructured":"National Cancer Institute. Drugs approved for colon and rectal cancer. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/colorectal (2024)."},{"key":"2129_CR400","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1038\/s41388-024-03183-1","volume":"43","author":"R Antoon","year":"2024","unstructured":"Antoon, R., Overdevest, N., Saleh, A. H. & Keating, A. Mesenchymal stromal cells as cancer promoters. Oncogene 43, 3545\u20133555 (2024).","journal-title":"Oncogene"},{"key":"2129_CR401","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0047-0","volume":"2","author":"W Chen","year":"2018","unstructured":"Chen, W., Hoffmann, A. D., Liu, H. & Liu, X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis. Oncol. 2, 4 (2018).","journal-title":"NPJ Precis. Oncol."},{"key":"2129_CR402","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.devcel.2019.04.012","volume":"49","author":"Y Gao","year":"2019","unstructured":"Gao, Y. et al. Metastasis organotropism: redefining the congenial soil. Dev. Cell 49, 375\u2013391 (2019).","journal-title":"Dev. Cell"},{"key":"2129_CR403","doi-asserted-by":"publisher","first-page":"1358786","DOI":"10.3389\/fonc.2024.1358786","volume":"14","author":"M Carrolo","year":"2024","unstructured":"Carrolo, M. et al. Metastatic organotropism: a brief overview. Front. Oncol. 14, 1358786 (2024).","journal-title":"Front. Oncol."},{"key":"2129_CR404","doi-asserted-by":"publisher","first-page":"13122","DOI":"10.1073\/pnas.0705824104","volume":"104","author":"JB Axelsen","year":"2007","unstructured":"Axelsen, J. B., Lotem, J., Sachs, L. & Domany, E. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc. Natl Acad. Sci. USA 104, 13122\u201313127 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2129_CR405","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1093\/bioinformatics\/btac493","volume":"38","author":"SFL Windels","year":"2022","unstructured":"Windels, S. F. L., Malod-Dognin, N. & Przulj, N. Identifying cellular cancer mechanisms through pathway-driven data integration. Bioinformatics 38, 4344\u20134351 (2022).","journal-title":"Bioinformatics"},{"key":"2129_CR406","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/bioinformatics\/btab847","volume":"38","author":"KP Jablonski","year":"2022","unstructured":"Jablonski, K. P., Pirkl, M., Cevid, D., Buhlmann, P. & Beerenwinkel, N. Identifying cancer pathway dysregulations using differential causal effects. Bioinformatics 38, 1550\u20131559 (2022).","journal-title":"Bioinformatics"},{"key":"2129_CR407","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01119-6","volume":"14","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. CTpathway: a CrossTalk-based pathway enrichment analysis method for cancer research. Genome Med. 14, 118 (2022).","journal-title":"Genome Med."},{"key":"2129_CR408","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41586-021-04393-3","volume":"602","author":"C Hu","year":"2022","unstructured":"Hu, C. et al. Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias. Nature 602, 518\u2013522 (2022).","journal-title":"Nature"},{"key":"2129_CR409","doi-asserted-by":"publisher","unstructured":"Xiong, D. et al. Structurally-informed human interactome reveals proteome-wide perturbations by disease mutations. bioRxiv https:\/\/doi.org\/10.1101\/2023.1104.1124.538110 (2024).","DOI":"10.1101\/2023.1104.1124.538110"},{"key":"2129_CR410","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41525-018-0051-x","volume":"3","author":"GY Lyu","year":"2018","unstructured":"Lyu, G. Y., Yeh, Y. H., Yeh, Y. C. & Wang, Y. C. Mutation load estimation model as a predictor of the response to cancer immunotherapy. NPJ Genom. Med. 3, 12 (2018).","journal-title":"NPJ Genom. Med."},{"key":"2129_CR411","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.molcel.2021.01.033","volume":"81","author":"R Mukherjee","year":"2021","unstructured":"Mukherjee, R. et al. Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Mol. Cell 81, 708\u2013723.e705 (2021).","journal-title":"Mol. Cell"},{"key":"2129_CR412","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.1039\/c3cp54253j","volume":"16","author":"CJ Tsai","year":"2014","unstructured":"Tsai, C. J. & Nussinov, R. The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation? Phys. Chem. Chem. Phys. 16, 6332\u20136341 (2014).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"2129_CR413","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-019-0564-y","volume":"52","author":"KC Akdemir","year":"2020","unstructured":"Akdemir, K. C. et al. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat. Genet. 52, 294\u2013305 (2020).","journal-title":"Nat. Genet."},{"key":"2129_CR414","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.118.016253","volume":"71","author":"F Cheng","year":"2019","unstructured":"Cheng, F., Liang, H., Butte, A. J., Eng, C. & Nussinov, R. Personal mutanomes meet modern oncology drug discovery and precision health. Pharm. Rev. 71, 1\u201319 (2019).","journal-title":"Pharm. Rev."},{"key":"2129_CR415","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.18632\/oncotarget.2439","volume":"5","author":"R Nussinov","year":"2014","unstructured":"Nussinov, R., Jang, H. & Tsai, C. J. The structural basis for cancer treatment decisions. Oncotarget 5, 7285\u20137302 (2014).","journal-title":"Oncotarget"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02129-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02129-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02129-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T18:03:18Z","timestamp":1739728998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02129-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":415,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02129-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}